BioLargo (BLGO) 10-Q 14 Aug 19 2019 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 12, 2019
Document Information [Line Items]
Entity Registrant Name	BIOLARGO, INC.
Entity Central Index Key	0000880242
Trading Symbol	blgo
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		157,380,022
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Amendment Flag	false
Title of 12(b) Security	Common Stock

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 706,000	$ 655,000
Accounts receivable	232,000	257,000
Inventories, net of allowance	38,000	26,000
Prepaid expenses and other current assets	25,000	17,000
Total current assets	1,001,000	955,000
In-process research and development (Note 8)	1,893,000	1,893,000
Equipment, net of depreciation	108,000	126,000
Other non-current assets	35,000	35,000
Right-of-use, operating lease, net of amortization	370,000
Deferred offering cost	176,000	176,000
Total assets	3,583,000	3,185,000
Current liabilities:
Accounts payable and accrued expenses	676,000	501,000
Notes payable	534,000	400,000
Line of credit	430,000	430,000
Convertible notes payable	2,863,000	1,365,000
Discount on convertible notes payable, and line of credit, net of amortization	(1,180,000)	(205,000)
Lease liability	116,000
Customer deposit	28,000
Total current liabilities	4,474,000	2,491,000
Long-term liabilities:
Long-term debt	210,000	1,292,000
Discount on convertible notes payable, net of amortization	(79,000)	(118,000)
Lease liability	254,000
Total long-term liabilities	1,028,000	1,817,000
Total liabilities	5,502,000	4,308,000
COMMITMENTS, CONTINGENCIES (Note 11)
STOCKHOLDERS’ EQUITY (DEFICIT):
Preferred Series A, $.00067 Par Value, 50,000,000 Shares Authorized, -0- Shares Issued and Outstanding, at December 31, 2018 and June 30, 2019, respectively.
Common stock, $.00067 Par Value, 400,000,000 Shares Authorized, 141,466,071 and 152,054,904 Shares Issued, at December 31, 2018 and June 30, 2019, respectively.	102,000	95,000
Additional paid-in capital	114,745,000	110,222,000
Accumulated other comprehensive loss	(98,000)	(90,000)
Accumulated deficit	(116,876,000)	(111,723,000)
Total BioLargo Inc. and Subsidiaries stockholders’ equity (deficit)	(2,127,000)	(1,496,000)
Non-controlling interest (Note 8)	208,000	373,000
Total stockholders’ equity (deficit)	(1,919,000)	(1,123,000)
Total liabilities and stockholders’ equity (deficit)	3,583,000	3,185,000
Scion Acquisition [Member] | Clyra Acquisition, Common Stock Redeemable for BioLargo Common Shares [Member]
Long-term liabilities:
Liability to Clyra Medical shareholder (Note 8)	643,000	643,000
Convertible Notes Issued by Clyra Medical Maturing on June 17, 2020 [Member]
Current liabilities:
Notes payable	1,007,000
Long-term liabilities:
Long-term debt		1,007,000
Convertible Notes Issued by Clyra Medical Maturing on June 17, 2020 [Member] | Scion Acquisition [Member]
Long-term liabilities:
Long-term debt	1,007,000
Convertible Notes and Notes Payable [Member]
Long-term liabilities:
Long-term debt	$ 210,000	$ 285,000

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Convertible Preferred Stock, Par Value (in dollars per share)	$ 0.00067	$ 0.00067
Convertible Preferred Stock, Shares Authorized (in shares)	50,000,000	50,000,000
Convertible Preferred Stock, Shares Issued (in shares)	0	0
Convertible Preferred Stock, Shares Outstanding (in shares)	0	0
Common Stock, Par Value (in dollars per share)	$ 0.00067	$ 0.00067
Common Stock, Shares Authorized (in shares)	400,000,000	400,000,000
Common Stock, Shares Issued (in shares)	152,054,904	141,466,071

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenues
Revenue	$ 426,000	$ 327,000	$ 790,000	$ 590,000
Cost of revenue
Gross profit	198,000	126,000	371,000	226,000
Selling, general and administrative expenses	1,302,000	1,316,000	2,696,000	2,486,000
Research and development	367,000	425,000	793,000	947,000
Depreciation expense	16,000	13,000	31,000	23,000
Operating loss	(1,487,000)	(1,628,000)	(3,149,000)	(3,230,000)
Other (expense) income:
Interest expense	(498,000)	(1,729,000)	(1,483,000)	(2,561,000)
Debt conversion expense		(276,000)		(276,000)
Loss on debt extinguishment	(44,000)		(228,000)
Grant income	42,000	33,000	124,000	38,000
Total other expense:	(500,000)	(1,972,000)	(1,587,000)	(2,799,000)
Net loss	(1,987,000)	(3,600,000)	(4,736,000)	(6,029,000)
Net loss attributable to noncontrolling interest	(192,000)	(95,000)	(365,000)	(202,000)
Net loss attributable to common shareholders	$ (1,795,000)	$ (3,505,000)	$ (4,371,000)	$ (5,827,000)
Net loss per share attributable to common shareholders:
Loss per share attributable to shareholders – basic and diluted (in dollars per share)	$ (0.01)	$ (0.03)	$ (0.03)	$ (0.05)
Weighted average number of common shares outstanding: (in shares)	145,700,515	118,748,451	143,983,182	111,760,954
Comprehensive loss:
Net loss	$ (1,987,000)	$ (3,600,000)	$ (4,736,000)	$ (6,029,000)
Foreign currency translation	(4,000)	13,000	(8,000)	1,000
Comprehensive loss	(1,991,000)	(3,587,000)	(4,744,000)	(6,028,000)
Comprehensive loss attributable to noncontrolling interest	(192,000)	(95,000)	(365,000)	(202,000)
Comprehensive loss attributable to common stockholders	(1,799,000)	(3,492,000)	(4,379,000)	(5,826,000)
Product [Member]
Revenues
Revenue	316,000	316,000	617,000	540,000
Cost of revenue
Cost of Goods and Services Sold	(136,000)	(194,000)	(276,000)	(328,000)
Service [Member]
Revenues
Revenue	110,000	11,000	173,000	50,000
Cost of revenue
Cost of Goods and Services Sold	$ (92,000)	$ (7,000)	$ (143,000)	$ (36,000)

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Stock Issued for Financing Fee [Member]Common Stock [Member]	Stock Issued for Financing Fee [Member]Additional Paid-in Capital [Member]	Stock Issued for Financing Fee [Member]	Extension of Convertible Note Maturity Date, Vista Capital [Member]Additional Paid-in Capital [Member]	Extension of Convertible Note Maturity Date, Vista Capital [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2017						104,164,465
Balance at Dec. 31, 2017						$ 70,000	$ 97,093,000	$ (101,205,000)	$ (62,000)	$ 695,000	$ (3,409,000)
Issuance of common stock for services (in shares)						714,436
Issuance of common stock for services							196,000				196,000
Issuance of common stock for interest (in shares)						617,072
Issuance of common stock for interest							165,000				165,000
Financing fee in stock (in shares)	252,385
Financing fee in stock		$ 85,000	$ 85,000
Sale of stock for cash (in shares)						658,226
Sale of stock for cash							168,000				168,000
Stock option compensation expense							320,000				320,000
Warrants and beneficial conversion feature issued as discount on convertible notes payable, note payable and line of credit							282,000				282,000
Deemed dividend							297,000	(297,000)
Net loss								(2,323,000)		(107,000)	(2,430,000)
Foreign currency translation									8,000		8,000
Balance (in shares) at Mar. 31, 2018						106,406,584
Balance at Mar. 31, 2018						$ 70,000	98,606,000	(103,825,000)	(54,000)	588,000	(4,615,000)
Balance (in shares) at Dec. 31, 2017						104,164,465
Balance at Dec. 31, 2017						$ 70,000	97,093,000	(101,205,000)	(62,000)	695,000	(3,409,000)
Net loss											(6,029,000)
Foreign currency translation											1,000
Balance (in shares) at Jun. 30, 2018						128,359,007
Balance at Jun. 30, 2018						$ 84,000	106,167,000	(107,330,000)	(61,000)	493,000	(645,000)
Balance (in shares) at Mar. 31, 2018						106,406,584
Balance at Mar. 31, 2018						$ 70,000	98,606,000	(103,825,000)	(54,000)	588,000	(4,615,000)
Issuance of common stock for services (in shares)						733,821
Issuance of common stock for services							250,000				250,000
Issuance of common stock for interest (in shares)						1,302,734
Issuance of common stock for interest						$ 1,000	327,000				329,000
Sale of stock for cash (in shares)						617,145
Sale of stock for cash							212,000				212,000
Warrants and beneficial conversion feature issued as discount on convertible notes payable, note payable and line of credit							32,000				33,000
Net loss								(3,505,000)		(95,000)	(3,600,000)
Foreign currency translation									(7,000)		13,000
Conversion of notes (in shares)						19,298,723
Conversion of notes						$ 13,000	6,215,000				6,228,000
Warrant exercise price reduction for cash							149,000				149,000
Balance (in shares) at Jun. 30, 2018						128,359,007
Balance at Jun. 30, 2018						$ 84,000	106,167,000	(107,330,000)	(61,000)	493,000	(645,000)
Balance (in shares) at Dec. 31, 2018						141,466,071
Balance at Dec. 31, 2018						$ 95,000	110,222,000	(111,723,000)	(90,000)	373,000	(1,123,000)
Issuance of common stock for services (in shares)						1,229,541
Issuance of common stock for services						$ 1,000	205,000				206,000
Issuance of common stock for interest (in shares)						139,362
Issuance of common stock for interest							25,000				25,000
Stock option compensation expense							352,000				352,000
Warrants and beneficial conversion feature issued as discount on convertible notes payable, note payable and line of credit							1,115,000				1,115,000
Deemed dividend							342,000	(342,000)
Net loss								(2,576,000)		(173,000)	(2,749,000)
Foreign currency translation									(4,000)		(4,000)
Conversion of notes (in shares)						1,638,479
Conversion of notes						$ 1,000	218,000				219,000
Warrant exercise price reduction for cash				$ 56,000	$ 56,000
Issuance of Clyra Medical common stock							21,000			89,000	110,000
Balance (in shares) at Mar. 31, 2019						144,473,453
Balance at Mar. 31, 2019						$ 97,000	112,556,000	(114,641,000)	(94,000)	289,000	(1,793,000)
Balance (in shares) at Dec. 31, 2018						141,466,071
Balance at Dec. 31, 2018						$ 95,000	110,222,000	(111,723,000)	(90,000)	373,000	(1,123,000)
Net loss											(4,736,000)
Foreign currency translation											(8,000)
Balance (in shares) at Jun. 30, 2019						152,555,174
Balance at Jun. 30, 2019						$ 102,000	114,745,000	(116,876,000)	(98,000)	208,000	(1,919,000)
Balance (in shares) at Mar. 31, 2019						144,473,453
Balance at Mar. 31, 2019						$ 97,000	112,556,000	(114,641,000)	(94,000)	289,000	(1,793,000)
Issuance of common stock for services (in shares)						981,684
Issuance of common stock for services							213,000				213,000
Issuance of common stock for interest (in shares)						87,748
Issuance of common stock for interest							15,000				15,000
Stock option compensation expense							296,000				296,000
Warrants and beneficial conversion feature issued as discount on convertible notes payable, note payable and line of credit							756,000				756,000
Deemed dividend							440,000	(440,000)
Net loss								(1,795,000)		(192,000)	(1,987,000)
Foreign currency translation									(4,000)		(4,000)
Conversion of notes (in shares)						2,767,833
Conversion of notes						$ 2,000	294,000				296,000
Issuance of Clyra Medical common stock							74,000			111,000	$ 185,000
Warrant exercise (in shares)						3,744,456					866,666
Warrant exercise						$ 3,000	101,000				$ 104,000
Stock issuance to officer (see note 7) (in shares)						500,000
Stock issuance to officer (see note 7)
Balance (in shares) at Jun. 30, 2019						152,555,174
Balance at Jun. 30, 2019						$ 102,000	$ 114,745,000	$ (116,876,000)	$ (98,000)	$ 208,000	$ (1,919,000)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash flows from operating activities
Net loss	$ (4,736,000)	$ (6,029,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	648,000	696,000
Common stock issued in lieu of salary to officers and fees for services from vendors	419,000	446,000
Common stock issued for interest	40,000	484,000
Interest expense related to amortization of the discount on convertible notes payable and line of credit and deferred financing costs	1,254,000	2,019,000
Interest expense related to the fair value of warrants issued as consent for variable debt	54,000
Debt conversion expense		276,000
Loss on extinguishment of debt	229,000
Bad debt expense		1,000
Deferred offering expense		8,000
Depreciation expense	31,000	23,000
Changes in assets and liabilities:
Accounts receivable	24,000	3,000
Inventories	(12,000)	28,000
Accounts payable and accrued expenses	178,000	31,000
Prepaid expenses and other current assets	(8,000)	(39,000)
Customer deposits	28,000
Net cash used in operating activities	(1,851,000)	(2,053,000)
Cash flows from investing activities
Leasehold improvements	(14,000)	(26,000)
Net cash used in investing activities	(14,000)	(26,000)
Cash flows from financing activities
Proceeds from convertible notes payable	1,825,000	463,000
Proceeds from conversion inducement		357,000
Proceeds from warrant exercise-price reduction		148,000
Proceeds from warrant exercise	104,000
Proceeds from the sale of stock in Clyra Medical	295,000
Repayment of note payable	(300,000)
Proceeds from sale of stock to Lincoln Park Capital		381,000
Proceeds from line of credit		390,000
Net cash provided by financing activities	1,924,000	1,739,000
Net effect of foreign currency translation	(8,000)	1,000
Net change in cash	51,000	(339,000)
Cash at beginning of year	655,000	990,000
Cash at end of period	706,000	651,000
Supplemental disclosures of cash flow information
Interest	40,000	5,000
Income taxes	3,000	5,000
Non-cash investing and financing activities
Fair value of warrants issued with convertible notes	1,817,000	225,000
Right of use, operating lease and liability	370,000
Deemed dividend	782,000	297,000
Conversion of Convertible Notes Payable into Common Stock [Member]
Non-cash investing and financing activities
Conversion of debt	515,000	530,000
Conversion of Convertible Notes Issued with Original Issue Discount [Member]
Non-cash investing and financing activities
Conversion of debt	373,000
Stock Issued for Exercise of Stock Options [Member]
Non-cash investing and financing activities
Fair value of stock issued		2,000
Stock Issued for Financing Fee [Member]
Non-cash investing and financing activities
Fair value of stock issued		$ 85,000

Note 1 - Business and Organizat

Note 1 - Business and Organization	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Description of Business BioLargo, Inc. delivers innovative and sustainable technology-based products and services, as well as environmental engineering expertise, across a broad range of industries with an overriding mission to “make life better” with a focus on clean water, clean air, and advanced wound care. Our business strategy is straightforward: we invent or acquire technologies that we believe have the potential to be disruptive in large commercial markets; we develop and validate these technologies to advance and promote their commercial success as we leverage our considerable scientific, engineering, and entrepreneurial talent; we then monetize these technical assets through a variety of business structures that may Liquidity / Going concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of our business. For the six June 30, 2019, $4,736,000, $1,851,000 June 30, 2019, $3,473,000 $1,001,000. not not December 31, 2019, December 31, 2018, six June 30, 2019, $1,364,000 $790,000 No 10, $2,119,000 12 4 12 $1,724,000in $145,000 September 6, 2019, $250,000 30 September 1, 2019. six June 30, 2019, $1,924,000 June 30, 2019 $706,000. June 30, 2019, $2,540,000 No The foregoing factors raise substantial doubt about our ability to continue as a going concern. Ultimately, our ability to continue as a going concern is dependent upon our ability to attract significant new sources of capital, attain a reasonable threshold of operating efficiencies and achieve profitable operations by licensing or otherwise commercializing products incorporating our technologies. The consolidated financial statements do not Organization We are a Delaware corporation formed in 1991. five 2006; No 2009; 2014; 2016; 2017 41.4% 2012, 2 8 The unaudited consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to Rule 8 03 X 1933, not six June 30, 2019 not may December 31, 2019, 10 December 31, 2018 March 29, 2019,

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 2. In the opinion of management, the accompanying balance sheet and related statements of operations, cash flows, and stockholders’ deficit include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally accepted in the United States of America. Principles of Consolidation The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, and Clyra Medical. Management believes Clyra Medical’s financial statements are appropriately consolidated with that of the Company after reviewing the guidance of ASC Topic 810, not 41% 8 Foreign Currency The Company has designated the functional currency of BioLargo Water, Inc., our Canadian subsidiary, to be the Canadian dollar. Therefore, translation gains and losses resulting from differences in exchange rates are recorded in accumulated other comprehensive income. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three one $250,000 not As of December 31, 2018 June 30, 2019, December 31, 2018 June 30, 2019 BioLargo, Inc. and wholly owned subsidiaries $ 193 $ 553 Clyra Medical Technologies, Inc. 462 153 Total $ 655 $ 706 Accounts Receivable Trade accounts receivable are recorded net of allowances for doubtful accounts. Estimates for allowances for doubtful accounts are determined based on payment history and individual customer circumstances. The allowance for doubtful accounts as of December 31, 2018 June 30, 2019 zero Credit Concentration We have a limited number of customers that account for significant portions of our revenue. During the six June 30, 2018 2019, two 10% June 30, 2018 June 30, 2019 Customer A 43 % 18 % Customer B 15 % 10 % We had four 10% December 31, 2018 June 30, 2019 December 31, 2018 June 30, 2019 Customer W 12 % 11 % Customer X 31 % <10 % Customer Y <10 % 10 % Customer Z <10 % 10 % Inventory Inventories are stated at the lower of cost or net realizable value using the average cost method. The allowance for obsolete inventory as of December 31, 2018 June 30, 2019 $3,000 December 31, 2018 June 30, 2019, December 31, 2018 June 30, 2019 Raw material $ 14 $ 26 Finished goods 12 12 Total $ 26 $ 38 Other Assets Other assets consisted of security deposits of $35,000 Impairment Long-lived and definite lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not December 31, 2018 June 30, 2019, no Earnings (Loss) Per Share We report basic and diluted earnings (loss) per share (“EPS”) for common and common share equivalents. Basic EPS is computed by dividing the loss attributable to common shareholders by the weighted average shares outstanding. Diluted EPS is computed by adding to the weighted average shares the dilutive effect if stock options and warrants were exercised into common stock. For the three six June 30, 2018 2019, Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period reported. Actual results could differ from those estimates. Estimates are used when accounting for stock-based transactions, debt transactions, derivative liabilities, allowance for bad debt, asset depreciation and amortization, among others. The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results of our financial statements. Share-Based Compensation Expense We recognize compensation expense for stock option awards on a straight-line basis for employees over the applicable service period of the award, which is the vesting period. We recognize compensation expense for stock option awards for non-employees at the fair value on the grant date. Generally, the options issued to non-employees have been earned upon issuance. For the instances that options are issued to non-employees with a vesting schedule, the fair value is recorded on each vesting date. Share-based compensation expense is based on the grant date fair value estimated using the Black-Scholes Option Pricing Model. For stock and stock options issued to consultants and other non-employees for services, the Company measures and records an expense as of the earlier of the date at which either: a commitment for performance by the non-employee has been reached or the non-employee’s performance is complete. The equity instruments are measured at the current fair value, and for stock options, the instruments are measured at fair value using the Black Scholes option model. The following methodology and assumptions were used to calculate share-based compensation for the six June 30, 2018 2019: 2018 2019 Non Plan 2018 Plan Non Plan 2018 Plan Risk free interest rate 2.43 - 2.91% 2.91 % 2.00 - 2.65% 2.00 - 2.65% Expected volatility 548 - 563% 548 % 147 - 152% 147 - 152% Expected dividend yield — — — — Forfeiture rate — — — — Life in years 7 7 7 7 Expected price volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Expected volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility. The risk-free interest rate used in the Black-Scholes calculation is based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve. We have never paid any cash dividends on our common stock and do not Historically, we have not Warrants Warrants issued with our convertible promissory notes, note payables, line of credit are accounted for under the fair value and relative fair value method. The warrant is first not. not If the warrant is determined to not The convertible note issued with the warrant is recorded at its fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant. Further, the convertible promissory note is examined for any intrinsic beneficial conversion feature (“BCF”) of which the convertible price of the note is less than the closing common stock price on date of issuance. If the relative fair value method is used to value the convertible promissory note and there is an intrinsic BCF, a further analysis is undertaken of the BCF using an effective conversion price which assumes the conversion price is the relative fair value divided by the number of shares the convertible debt is converted into by its terms. The BCF value is accounted for as equity. The warrant and BCF relative fair values are also recorded as a discount to the convertible promissory notes. As presented, these equity features of the convertible promissory notes have recorded a discount to the convertible notes that is substantially equal to the proceeds received. Non-Cash Transactions We have established a policy relative to the methodology to determine the value assigned to each intangible we acquire, and/or services or products received for non-cash consideration of our common stock. The value is based on the market price of our common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered or product is received. Revenue Recognition We adopted ASU 2014 09, 606, January 1, 2018. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Step 2: Step 3: Step 4: Step 5: For product revenue, we identify the contract with the customer through a written purchase order (which may For service revenue, we identify services to be performed in a written contract, which specifies the performance obligations and the rate at which the services will be billed. Each service is separately negotiated and priced. Revenue is recognized as services are performed and completed. Service contracts typically call for invoicing for time and materials incurred for that contract. To date, there have been no In the future, we may one Government Grants We have been awarded multiple research grants from governmental and quasi-governmental institutions. The grants received are considered “other income” and are included in our Consolidated Statements of Operations and Comprehensive Loss. We received our first 2015 60 $3.6 third third six eighteen not The grants typically provide for (i) recurring monthly amounts, (ii) reimbursement of costs for research talent for which we invoice to request payment, and (iii) ancillary cost reimbursement for research talent travel related costs. All awarded grants have specific requirements on how the money is spent, typically to employ researchers. None may Not no Income Taxes The asset and liability approach is used to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of asset and liabilities. Deferred tax assets and liabilities are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect on deferred tax asset and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. We account for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by generally accepted accounting principles (“GAAP”). Under GAAP, the tax effects of a position are recognized only if it is “more-likely-than- not” not not” no Fair Value of Financial Instruments Management believes the carrying amounts of the Company’s financial instruments (excluding debt and equity instruments) as of December 31, 2018 June 30, 2019 Tax Credits Our research and development activities in Canada may not Recent Accounting Pronouncements In August 2018, No. 2018 13, 820 820, December 15, 2019, not not In June 2018, No. 2018 07, 718 718 718 718 718 not 1 2 606, December 15, 2018, not In February 2016, No. 2016 02, January 1, 2019 July 2018, $399,000 may June 30, 2019, $370,000.

Note 3 - Lincoln Park Financing

Note 3 - Lincoln Park Financing	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Stock Purchase Agreement [Text Block]	Note 3. On August 25, 2017, $10 three may three 12 no first may not We did not six June 30, 2019. six June 30, 2018, 1,256,751 $381,000. 18,260 We record stock sales in our equity statement and the additional commitment shares issued reduce the deferred offering costs on our balance sheet.

Note 4 - Debt Obligations

Note 4 - Debt Obligations	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 4. The following table summarizes our debt obligations outstanding as of December 31, 2018 June 30, 2019 ( $2,360,000 June 30, 2019, 12 December 31, 2018 June 30, Current liabilities: Notes payable and line of credit Notes payable, mature September 6, 2019 $ 400 $ 484 Note payable, due on demand 60 days’ notice (or March 8, 2023) — 50 Line of credit, due on demand 30 days’ notice after September 1, 2019 430 430 Note payable issued by Clyra Medical to Scion, matures June 17, 2020 (Note 8) — 1,007 Total notes payable and line of credit $ 830 $ 1,971 Convertible notes payable: Convertible note, matured January 11, 2019 300 — Convertible notes, mature December 31, 2019 (1) 75 75 Convertible note, matures July 15, 2019 550 125 Convertible note, matures July 20, 2019 (1) 440 440 Convertible note, matures October 7, 2019 — 370 Convertible notes, mature November 5, 2019 and December 7, 2019 — 554 Convertible nine-month OID notes, mature beginning October 2019 — 213 Convertible note, matures April 18, 2020 — 220 Convertible notes, mature February 14 and March 17, 2020 — 200 Convertible note, matures March 4, 2020 — 110 Convertible 12-month OID notes, mature beginning June 2020 — 531 Convertible notes payable, mature June 20, 2020 (1) — 25 Total convertible notes payable $ 1,365 $ 2,863 Total current liabilities $ 2,195 $ 4,834 Long-term liabilities: Note payable issued by Clyra Medical to Scion, matures June 17, 2020 (See Note 8) 1,007 — Convertible notes payable, mature June 20, 2020 (1) 25 — Convertible notes payable, mature April 20, 2021 (1) 100 100 Convertible notes, mature June 15, 2021 (1) 110 110 Note payable, matures March 8, 2023 (or on demand 60 days’ notice) 50 — Total long-term liabilities $ 1,292 $ 210 Total $ 3,487 $ 5,044 ( 1 The following discussion includes debt instruments to which amendments were made during the three June 30, 2019, March 29, 2019. BIOLARGO, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) Notes payable, mature September 6, 2019 On June 4, 2019, two June 5, 2019 September 19, 2018 10%, two $484,000 June 4, 2019. June 30, 2019, one two 12 Convertible Note, matures July 15, 2019 ( On January 7, 2019, December 14, 2017 ( 2017 April 15, 2019. $605,100. five 80% 25 20% 15%, 15% 30% 25% $487,000, six June 30, 2019. On March 28, 2019, 2017 July 15, 2019. 10 $420,000. $38,000 July 16, 2019, August 31, 2019. No 12 During the six June 30, 2019, $515,000 2017 4,406,312 June 30, 2019, $125,000. June 30, 2019, February 28, 2020 ( 12 Convertible Note, matures October 7, 2019 ( On January 7, 2019, $300,000 2019 $330,000, nine October 7, 2019). 2019 one 12%, 2019 65% 25 2019 4.99% 2019 2019 not November 6, 2018). $300,000, 2019. June 30, 2019, April 7, 2020 ( 12 Convertible Notes, mature November 5, 2019 December 7, 2019 ( On January 31, 2019, 12% $495,000 two nine 12% $300,000 February 5, 2019, $330,000 10% November 5, 2019. second $150,000, March 7, 2019, $495,000. second December 7, 2019. $554,000. BIOLARGO, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) The Tangiers Note is convertible at the option of Tangiers at a conversion price equal to 75% 25 $185,000, 2019. We may 180 90 25%; 91 180 30%. may not 144 10 six may 22% 25% In connection with the Tangiers Note, the Company caused its transfer agent to reserve 3,000,000 On July 29, 2019, $369,600 $350,000 12 Convertible Nine-Month OID Notes During the three March 31, 2019, $213,000, 25% $0.25 nine may $0.25. 75% $0.25 6 On June 7, 2019, twelve $0.17; $0.17, 300,000 Convertible Note, matures April 18, 2020 On April 18, 2019, $188,000 $220,000 10% $10,000 April 18, 2020 10% may $400,000 two two one The Bellridge Note is convertible at the option of Bellridge at a conversion price equal to 70% 25 may 90 125% 130% 24% $120,000, twelve BIOLARGO, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) Convertible notes, mature February 14 March 17, 2020 On May 14, 2019, $95,000 $110,000 10% $5,000 nine February 14, 2020. On June 17, 2019, second $77,000 $90,000, 10% $5,000 nine March 17, 2020. Concurrently with these two 70% 25 may 180 5% first 30 30% 30. 24% $134,000, nine Convertible note, matures March 4, 2020 On June 4, 2019, $95,000 $110,000 10% $5,000 nine March 4, 2020, 10% The EMA Note is convertible at the option of EMA at a conversion price equal to 70% 25 may 90 125% 130% 24% $77,000, nine Convertible Twelve-month OID notes During the three June 30, 2019, $425,000 “12 $531,000, 25% four $106,000 $425,000, twelve June 7, 2020. Each Twelve-month OID Note is convertible by the investor at any time at $0.17 $0.17. five 5% may 10 may We must prepay the OID Notes upon the conclusion of a “qualifying offering” (an offering raising $3.5 not not seventy 70% 25 In addition to the note, each OID investor will receive a warrant to purchase common stock exercisable at $0.25 6 Subsequent to June 30, 2019, 12 12 BIOLARGO, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Note 5 - Share-based Compensati

Note 5 - Share-based Compensation	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	Note 5. Issuance of Common Stock in exchange for payment of payables Payment of Officer Salaries On March 29, 2019, 579,996 $93,000 two $0.16 2018 On June 28, 2019, 465,875 $107,000 two $0.23 2018 On March 31, 2018, 323,030 $84,000 two $0.26 On June 29, 2018, 176,947 $76,000 two $0.43 Payment of Consultant Fees During the three June 30, 2019, 515,809 $0.16 $0.23 $107,000 During the three June 30, 2018, 556,874 $0.17 $0.23 $174,000 Payment of Interest on Notes During the three June 30, 2019, 87,478 $0.23 $0.43 $15,000 During the three June 30, 2018, 1,302,734 $0.23 $0.45 $329,000 Restricted Stock Units On May 28, 2019, No 500,000 $3,000,000 $3,000,000 12 Stock Option Expense During the six June 30, 2018 2019, $696,000 $648,000, 2018 BIOLARGO, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) 2018 On June 22, 2018, 2018 “2018 may 10 2018 40 2018 January 1 st 2 Activity for our stock options under the 2018 June 30, 2018 December 31, 2018 six June 30, 2019, Weighted Average Aggregate Options Exercise Price per intrinsic As of June 30, 2018: Outstanding Price per share share Value (1) Inception, June 22, 2018 — — — Granted 296,976 0.43 0. 43 Balance, June 30, 2018 296,976 $ 0.43 $ 0.43 $ — Weighted Average Aggregate Options Exercise Price per intrinsic As of June 30, 2019: Outstanding Price per share share Value (1) Balance, December 31, 2018 1,318,517 $0.22 – 0.43 $ 0.30 Granted 3,728,366 0.16 – 0.22 0.18 Expired — — — Balance, June 30, 2019 5,046,833 $0.16 – 0.43 $ 0.21 $ 109,000 ( 1 $0.23 June 30, 2019. The options to purchase 3,528,366 six June 30, 2019 513,012 $0.16 $0.25 $93,000 715,354 $0.16 $0.23 300,000 $0.22 1,000,000 $0.17 1,200,000 $0.17 2018 six June 30, 2019, $137,000 Chief Financial Officer Contract Extension On January 16, 2019, February 1, 2008 ( January 16, 2019 ( September 30, 2019 ( September 30, 2018. December 31, 2018 BIOLARGO, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) For the Extended Term, Mr. Dargan was issued an option (“Option”) to purchase 300,000 January 16, 2019 $0.22, January 16, 2029, 75,000 June 30, 2019, 25,000 January 31, 2019, 2018 $67,000, $50,000 six June 30, 2019. The issuance of the Option is Mr. Dargan’s sole source of compensation for the Extended Term. As was the case in all prior terms of his engagement, there is no no not Vice President of Operations Contract Extension On May 28, 2019, 1,200,000 2018 first 200,000 May 28 $0.17 third third first third second $34,000 1,000,000 No none no July 5, 2019, 300,000 July 5 ( $0.25 100,000 second third Vice President of Sales On May 28, 2019, 1,200,000 2018 first 200,000 May 28 $0.17 third third first third second $34,000 1,000,000 No none no July 5, 2019, 300,000 July 5 ( $0.25 100,000 second third 2007 On September 7, 2007, April 29, 2011, 2007 “2007 may 10 September 7, 2017. September 2017, Activity for our stock options under the 2007 six June 30, 2018 2019 Weighted Average Aggregate Options Exercise Price per intrinsic As of June 30, 2018: Outstanding price per share share Value (1) Balance, December 31, 2017 9,831,586 $0.23 – 1.89 $ 0.44 Expired (70,000 ) 1.45 – 1.89 1.79 Balance, June 30, 2018 9,761,586 $0.23 – 1.65 $ 0.43 $ — As of June 30, 2019: Balance, December 31, 2018 9,691,586 $0.23 – 0.94 $ 0.43 Expired (842,136 ) 0.28 – 0.70 0.49 Balance, June 30, 2019 8,849,451 $0.23 – 1.65 $ 0.46 $ — ( 1 $0.23 June 30, 2019. BIOLARGO, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) Non-Plan Options issued During the six June 30, 2019, 970,380 $0.16 $0.25 $194,000. six June 30, 2019 $367,000, During the six June 30, 2018, 1,008,268 $0.23 $0.43 $261,000 Activity of our non-plan stock options issued for the six June 30, 2018 2019 Weighted Non-plan average Aggregate Options Exercise price per intrinsic As of June 30, 2018: outstanding price per share share value (1) Balance, December 31, 2017 20,018,408 $0.25 – 1.00 $ 0.51 Granted 1,008,268 0.23 – 0.43 0.26 Expired (2,400,000 ) 0.99 0.99 Balance, June 30, 2018 18,626,676 $0.25 – 1.00 $ 0.45 $ — As of June 30, 2019: Balance, December 31, 2018 19,319,496 $0.23 – 1.00 $ 0.43 Granted 970,380 0.16 – 0.25 0.19 Expired (691,975 ) 0.55 0.55 Balance, June 30, 2019 19,597,901 $0.16 – 1.00 $ 0.42 $ 34,000 ( 1 $0.23 June 30, 2019.

Note 6 - Warrants

Note 6 - Warrants	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Warrants [Text Block]	Note 6. We have certain warrants outstanding to purchase our common stock, at various prices, as described in the following table: Weighted average Aggregate Warrants Exercise price per intrinsic As of June 30, 2018: outstanding price per share share value (1) Balance, December 31, 2017 22,104,817 $0.125 – 1.00 $ 0.45 Issued 2,611,513 0.25 – 0.48 0.35 Expired (2,683,400 ) 0.40 0.40 Balance, June 30, 2018 22,032,930 $0.125 – 1.00 $ 0.44 As of June 30, 2019: Balance, December 31, 2018 26,872,430 $0.25 – 1.00 $ 0.42 Issued 9,031,871 0.10 – 0.25 0.15 Exercised (5,205,746 ) 0.10 – 0.12 0.11 Balance, June 30, 2019 30,698,555 $0.10 – 1.00 $ 0.39 $ 547,000 Warrants issued as part of debt extension On March 5, 2019, 4, Notes payable, mature September 6, 2019 1,387,500 $0.25 September 19, 2023. $0.20 1,734,375. $346,875 600,000 750,000 $0.20 $56,000 three March 31, 2019. two 496,875. Warrants issued as consent for variable rate debt On January 7 January 31, 2019, August 25, 2017, 300,000 $0.25 five not $54,000 2019 4 Warrants Issued concurrently with the Nine-month OID notes In conjunction with the issuance of our nine 4 $0.25 5 three March 31, 2019, 637,500 three $89,000 three June 30, 2019, $0.25 $0.17, 300,000 937,500, $85,000, Warrants Issued concurrently with Twelve-month OID notes During the three June 30, 2019, 2,619,485 4 $0.25 5 75% $0.17 $300,000 $375,000, 1,654,412 18 not not $252,000 Warrants exercised During the three June 30, 2019, $104,000 866,666 During the three June 30, 2019, September 12, 2018, 2,877,790 $355,000, Fair Value To determine interest expense related to our outstanding warrants issued in conjunction with debt offerings, the fair value of each award grant is estimated on the date of grant using the Black-Scholes option pricing model and the relative fair values are amortized over the life of the warrant. For the determination of expense of warrants issued for services, extinguishment of debt and settlement management also uses the option-pricing model. The principal assumptions we used in applying this model were as follows: June 30, 2018 June 30, 2019 Risk free interest rate 2.54% 1.70 – 2.62% Expected volatility 252% 86 – 110% Expected dividend yield — — Forfeiture rate — — Expected life in years 5 – 10 2 – 5 The risk-free interest rate is based on U.S. Treasury yields in effect at the time of grant. Expected volatilities are based on historical volatility of our common stock. The expected life in years is based on the contract term of the warrant.

Note 7 - Accounts Payable and A

Note 7 - Accounts Payable and Accrued Expenses	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 7. Accounts payable and accrued expenses included the following (in thousands): December 31, 2018 June 30, 2019 Accounts payable and accrued expense $ 302 $ 328 Accrued interest 122 209 Accrued payroll 77 139 Total accounts payable and accrued expenses $ 501 $ 676

Note 8 - Noncontrolling Interes

Note 8 - Noncontrolling Interest - Clyra Medical	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 8. We consolidate the operations of our partially owned subsidiary Clyra Medical (see Note 2 Acquisition of In-process Research and Development On September 26, 2018, 21,000 10,000 7,142,858 $1,250,000 $1 On December 17, 2018, $1 one 15,500 one fifth $100,000 $100,000 $500,000 $1 $2 Scion Solutions – Note Payable and Clyra Liability The promissory note in the principal amount of $1,250,000 September 26, 2018 ( 5%. 25% not 18 12 18 25% 12 5% June 30, 2019, $1,007,000. Non-Controlling Interest During the six June 30, 2019, $295,000 $200 As of June 30, 2019, Shareholder Shares Percent BioLargo, Inc. 28,053 41.4% Sanatio Capital (1) 11,520 17.0% Scion Solutions (2) 15,500 22.9% Other 12,697 18.7% Total 67,770 Notes: ( 1 9,830 1,690 ( 2 not 15,500 Sanatio Capital purchased Series A Preferred shares in 2015. 8% five no 510 December 20, no June 30, 2019 $215,000. Holders of Preferred Shares are entitled to preferential payments in the event of a liquidation, dissolution or winding up of the company, in an amount equal to any accrued and unpaid dividends. After such preference, any remaining assets are distributed pro-rata between holders of Clyra Medical common stock and Preferred Shares as if the Preferred Shares had converted to Clyra Medical common stock. Holders of Preferred Shares may one one Preferred shares may one one one one

Note 9 - BioLargo Engineering,

Note 9 - BioLargo Engineering, Science and Technologies, LLC	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Wholly-Owned Subsidiary [Text Block]	Note 9. In September 2017, three seven 10 two 100% no five 30% 2 five March 31, 2018 ( not 90% 10% first No

Note 10 - Business Segment Info

Note 10 - Business Segment Information	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 10. BioLargo currently has four four 1. No 2. 510 3. 4. Historically, none No third December 31, 2018, No $417,000 $500,000 2017 $1 2018 six June 30, 2019, $54,000 The segment information for the three six June 30, 2018 2019, Three months ended June 30, Six months ended June 30, 2018 2019 2018 2019 Revenue Odor-No-More $ 316 $ 315 $ 540 $ 616 BLEST 161 241 350 424 BLEST - Intercompany revenue (150 ) (130 ) (300 ) (250 ) Total $ 327 $ 426 $ 590 $ 790 Operating loss BioLargo corporate $ (1,052 ) $ (956 ) $ (2,145 ) $ (1,904 ) Odor-No-More (145 ) (51 ) (254 ) (141 ) Clyra (177 ) (319 ) (376 ) (606 ) BLEST (70 ) (27 ) (115 ) (137 ) Water (184 ) (134 ) (340 ) (361 ) Total $ (1,628 ) $ (1,487 ) $ (3,230 ) $ (3,149 ) Interest expense BioLargo Corporate $ (1,729 ) $ (485 ) $ (2,559 ) $ (1,458 ) Clyra — (13 ) (2 ) (25 ) Total $ (1,729 ) $ (498 ) $ (2,561 ) $ (1,483 ) Research and development expense BioLargo Corporate $ (281 ) $ (210 ) $ (624 ) $ (382 ) Odor-No-More — — — — Clyra (57 ) (106 ) (144 ) (155 ) BLEST (105 ) (73 ) (205 ) (195 ) Water (132 ) (108 ) (274 ) (317 ) Intersegement BioLargo corporate 150 130 300 256 Total $ (425 ) $ (367 ) $ (947 ) $ (793 ) As of June 30, 2019 BioLargo ONM Clyra BLEST Water Elimination Total Tangible assets $ 1,000 $ 198 $ 302 $ 163 $ 33 $ (6 ) $ 1,690 Intangible assets 1,893 — — — — — 1,893 As of December 31, 2018 BioLargo ONM Clyra BLEST Water Elimination Total Tangible assets $ 353 $ 220 $ 462 $ 230 $ 33 $ (6 ) $ 1,292 Intangible assets 1,893 — — — — — 1,893

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 11. Provenzano Employment Agreement On June 18, 2019, No January 1, 2008. The Provenzano Employment Agreement provides that Mr. Provenzano will serve as our Executive Vice President of Operations, as well as the President and Chief Executive Officer of our wholly owned subsidiary Odor- No $169,772 four may In conjunction with this agreement, our Compensation Committee awarded Mr. Provenzano an option to purchase common stock and restricted stock units under our 2018 5 The Provenzano Employment Agreement has a term of five may 120 360 one one one one The Provenzano Employment Agreement requires Mr. Provenzano to keep certain information confidential, not Office Leases We have long-term operating leases for office, industrial and laboratory space in Westminster, California, Oak Ridge, Tennessee, and Alberta, Canada. Payments made under operating leases are charged to the Consolidated Statement of Operations and Comprehensive Loss on a straight-line basis over the term of the operating lease agreement. For the six June 30, 2018 2019, $108,000 $104,000, January 1, 2019, 842 not 4 18%. $699,000. not The leases have no not Clyra Medical Consulting Agreement Our partially owned subsidiary Clyra Medical (see Note 8 8 $23,000 four not $1.1

Note 12 - Subsequent Events

Note 12 - Subsequent Events	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	Note 12. Management has evaluated subsequent events through the date of the filing of this report and management noted the following for disclosure. Financing activities Subsequent to June 30, 2019, $2,360,000 $180,000 $1,313,800 Subsequent to June 30, 2019, $1,410,000 4, $1,762,500, 7,775,735 $0.25 6 12 July 29, 2019. On August 9, 2019, $600,000 one $600,000, two 15% $0.30 1,200,000 $0.30 five Subsequent to June 30, 2019, 1.5 $180,000. On July 29, 2019, $330,000 $39,600 January 31, 2019, 2,640,000 $350,000 4 $437,500, 1,930,147 Three holders of a secured line of credit issued in 2018 $205,000 $256,250, 1,130,515 On the July 20, 2019 $440,000 2,000 $105,600 384,980 $0.2743 20 3% 38.9%. A holder of a note in the principal amount of $338,800, September 6, 2019, 12 25% 4, September 6, 2019”.) $41,200 $475,000, 2,095,588 $0.17 18% 5% five may $0.25 18 On August 13, 2019, six two first $125,000, February 28, 2020, second $330,000, April 7, 2020. In summary, since June 30, 2019, $2,540,000 $1,313,800 $2,931,250 $600,000

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, and Clyra Medical. Management believes Clyra Medical’s financial statements are appropriately consolidated with that of the Company after reviewing the guidance of ASC Topic 810, not 41% 8
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency The Company has designated the functional currency of BioLargo Water, Inc., our Canadian subsidiary, to be the Canadian dollar. Therefore, translation gains and losses resulting from differences in exchange rates are recorded in accumulated other comprehensive income.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three one $250,000 not As of December 31, 2018 June 30, 2019, December 31, 2018 June 30, 2019 BioLargo, Inc. and wholly owned subsidiaries $ 193 $ 553 Clyra Medical Technologies, Inc. 462 153 Total $ 655 $ 706
Receivable [Policy Text Block]	Accounts Receivable Trade accounts receivable are recorded net of allowances for doubtful accounts. Estimates for allowances for doubtful accounts are determined based on payment history and individual customer circumstances. The allowance for doubtful accounts as of December 31, 2018 June 30, 2019 zero
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Concentration We have a limited number of customers that account for significant portions of our revenue. During the six June 30, 2018 2019, two 10% June 30, 2018 June 30, 2019 Customer A 43 % 18 % Customer B 15 % 10 % We had four 10% December 31, 2018 June 30, 2019 December 31, 2018 June 30, 2019 Customer W 12 % 11 % Customer X 31 % <10 % Customer Y <10 % 10 % Customer Z <10 % 10 %
Inventory, Policy [Policy Text Block]	Inventory Inventories are stated at the lower of cost or net realizable value using the average cost method. The allowance for obsolete inventory as of December 31, 2018 June 30, 2019 $3,000 December 31, 2018 June 30, 2019, December 31, 2018 June 30, 2019 Raw material $ 14 $ 26 Finished goods 12 12 Total $ 26 $ 38
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Other Assets Other assets consisted of security deposits of $35,000
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Impairment Long-lived and definite lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not December 31, 2018 June 30, 2019, no
Earnings Per Share, Policy [Policy Text Block]	Earnings (Loss) Per Share We report basic and diluted earnings (loss) per share (“EPS”) for common and common share equivalents. Basic EPS is computed by dividing the loss attributable to common shareholders by the weighted average shares outstanding. Diluted EPS is computed by adding to the weighted average shares the dilutive effect if stock options and warrants were exercised into common stock. For the three six June 30, 2018 2019,
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period reported. Actual results could differ from those estimates. Estimates are used when accounting for stock-based transactions, debt transactions, derivative liabilities, allowance for bad debt, asset depreciation and amortization, among others. The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results of our financial statements.
Share-based Payment Arrangement [Policy Text Block]	Share-Based Compensation Expense We recognize compensation expense for stock option awards on a straight-line basis for employees over the applicable service period of the award, which is the vesting period. We recognize compensation expense for stock option awards for non-employees at the fair value on the grant date. Generally, the options issued to non-employees have been earned upon issuance. For the instances that options are issued to non-employees with a vesting schedule, the fair value is recorded on each vesting date. Share-based compensation expense is based on the grant date fair value estimated using the Black-Scholes Option Pricing Model. For stock and stock options issued to consultants and other non-employees for services, the Company measures and records an expense as of the earlier of the date at which either: a commitment for performance by the non-employee has been reached or the non-employee’s performance is complete. The equity instruments are measured at the current fair value, and for stock options, the instruments are measured at fair value using the Black Scholes option model. The following methodology and assumptions were used to calculate share-based compensation for the six June 30, 2018 2019: 2018 2019 Non Plan 2018 Plan Non Plan 2018 Plan Risk free interest rate 2.43 - 2.91% 2.91 % 2.00 - 2.65% 2.00 - 2.65% Expected volatility 548 - 563% 548 % 147 - 152% 147 - 152% Expected dividend yield — — — — Forfeiture rate — — — — Life in years 7 7 7 7 Expected price volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Expected volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility. The risk-free interest rate used in the Black-Scholes calculation is based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve. We have never paid any cash dividends on our common stock and do not Historically, we have not
Warrant Policy [Policy Text Block]	Warrants Warrants issued with our convertible promissory notes, note payables, line of credit are accounted for under the fair value and relative fair value method. The warrant is first not. not If the warrant is determined to not The convertible note issued with the warrant is recorded at its fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant. Further, the convertible promissory note is examined for any intrinsic beneficial conversion feature (“BCF”) of which the convertible price of the note is less than the closing common stock price on date of issuance. If the relative fair value method is used to value the convertible promissory note and there is an intrinsic BCF, a further analysis is undertaken of the BCF using an effective conversion price which assumes the conversion price is the relative fair value divided by the number of shares the convertible debt is converted into by its terms. The BCF value is accounted for as equity. The warrant and BCF relative fair values are also recorded as a discount to the convertible promissory notes. As presented, these equity features of the convertible promissory notes have recorded a discount to the convertible notes that is substantially equal to the proceeds received.
Non Cash Transactions [Policy Text Block]	Non-Cash Transactions We have established a policy relative to the methodology to determine the value assigned to each intangible we acquire, and/or services or products received for non-cash consideration of our common stock. The value is based on the market price of our common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered or product is received.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition We adopted ASU 2014 09, 606, January 1, 2018. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Step 2: Step 3: Step 4: Step 5: For product revenue, we identify the contract with the customer through a written purchase order (which may For service revenue, we identify services to be performed in a written contract, which specifies the performance obligations and the rate at which the services will be billed. Each service is separately negotiated and priced. Revenue is recognized as services are performed and completed. Service contracts typically call for invoicing for time and materials incurred for that contract. To date, there have been no In the future, we may one
Government Grants [Policy Text Block]	Government Grants We have been awarded multiple research grants from governmental and quasi-governmental institutions. The grants received are considered “other income” and are included in our Consolidated Statements of Operations and Comprehensive Loss. We received our first 2015 60 $3.6 third third six eighteen not The grants typically provide for (i) recurring monthly amounts, (ii) reimbursement of costs for research talent for which we invoice to request payment, and (iii) ancillary cost reimbursement for research talent travel related costs. All awarded grants have specific requirements on how the money is spent, typically to employ researchers. None may Not no
Income Tax, Policy [Policy Text Block]	Income Taxes The asset and liability approach is used to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of asset and liabilities. Deferred tax assets and liabilities are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect on deferred tax asset and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. We account for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by generally accepted accounting principles (“GAAP”). Under GAAP, the tax effects of a position are recognized only if it is “more-likely-than- not” not not” no
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Management believes the carrying amounts of the Company’s financial instruments (excluding debt and equity instruments) as of December 31, 2018 June 30, 2019
Tax Credits [Policy Text Block]	Tax Credits Our research and development activities in Canada may not
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In August 2018, No. 2018 13, 820 820, December 15, 2019, not not In June 2018, No. 2018 07, 718 718 718 718 718 not 1 2 606, December 15, 2018, not In February 2016, No. 2016 02, January 1, 2019 July 2018, $399,000 may June 30, 2019, $370,000.

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Cash and Cash Equivalents [Table Text Block]	December 31, 2018 June 30, 2019 BioLargo, Inc. and wholly owned subsidiaries $ 193 $ 553 Clyra Medical Technologies, Inc. 462 153 Total $ 655 $ 706
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	June 30, 2018 June 30, 2019 Customer A 43 % 18 % Customer B 15 % 10 % December 31, 2018 June 30, 2019 Customer W 12 % 11 % Customer X 31 % <10 % Customer Y <10 % 10 % Customer Z <10 % 10 %
Schedule of Inventory, Current [Table Text Block]	December 31, 2018 June 30, 2019 Raw material $ 14 $ 26 Finished goods 12 12 Total $ 26 $ 38
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2018 2019 Non Plan 2018 Plan Non Plan 2018 Plan Risk free interest rate 2.43 - 2.91% 2.91 % 2.00 - 2.65% 2.00 - 2.65% Expected volatility 548 - 563% 548 % 147 - 152% 147 - 152% Expected dividend yield — — — — Forfeiture rate — — — — Life in years 7 7 7 7

Note 4 - Debt Obligations (Tabl

Note 4 - Debt Obligations (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Debt [Table Text Block]	December 31, 2018 June 30, Current liabilities: Notes payable and line of credit Notes payable, mature September 6, 2019 $ 400 $ 484 Note payable, due on demand 60 days’ notice (or March 8, 2023) — 50 Line of credit, due on demand 30 days’ notice after September 1, 2019 430 430 Note payable issued by Clyra Medical to Scion, matures June 17, 2020 (Note 8) — 1,007 Total notes payable and line of credit $ 830 $ 1,971 Convertible notes payable: Convertible note, matured January 11, 2019 300 — Convertible notes, mature December 31, 2019 (1) 75 75 Convertible note, matures July 15, 2019 550 125 Convertible note, matures July 20, 2019 (1) 440 440 Convertible note, matures October 7, 2019 — 370 Convertible notes, mature November 5, 2019 and December 7, 2019 — 554 Convertible nine-month OID notes, mature beginning October 2019 — 213 Convertible note, matures April 18, 2020 — 220 Convertible notes, mature February 14 and March 17, 2020 — 200 Convertible note, matures March 4, 2020 — 110 Convertible 12-month OID notes, mature beginning June 2020 — 531 Convertible notes payable, mature June 20, 2020 (1) — 25 Total convertible notes payable $ 1,365 $ 2,863 Total current liabilities $ 2,195 $ 4,834 Long-term liabilities: Note payable issued by Clyra Medical to Scion, matures June 17, 2020 (See Note 8) 1,007 — Convertible notes payable, mature June 20, 2020 (1) 25 — Convertible notes payable, mature April 20, 2021 (1) 100 100 Convertible notes, mature June 15, 2021 (1) 110 110 Note payable, matures March 8, 2023 (or on demand 60 days’ notice) 50 — Total long-term liabilities $ 1,292 $ 210 Total $ 3,487 $ 5,044

Note 5 - Share-based Compensa_2

Note 5 - Share-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Average Aggregate Options Exercise Price per intrinsic As of June 30, 2018: Outstanding Price per share share Value (1) Inception, June 22, 2018 — — — Granted 296,976 0.43 0. 43 Balance, June 30, 2018 296,976 $ 0.43 $ 0.43 $ — Weighted Average Aggregate Options Exercise Price per intrinsic As of June 30, 2019: Outstanding Price per share share Value (1) Balance, December 31, 2018 1,318,517 $0.22 – 0.43 $ 0.30 Granted 3,728,366 0.16 – 0.22 0.18 Expired — — — Balance, June 30, 2019 5,046,833 $0.16 – 0.43 $ 0.21 $ 109,000 Weighted Average Aggregate Options Exercise Price per intrinsic As of June 30, 2018: Outstanding price per share share Value (1) Balance, December 31, 2017 9,831,586 $0.23 – 1.89 $ 0.44 Expired (70,000 ) 1.45 – 1.89 1.79 Balance, June 30, 2018 9,761,586 $0.23 – 1.65 $ 0.43 $ — As of June 30, 2019: Balance, December 31, 2018 9,691,586 $0.23 – 0.94 $ 0.43 Expired (842,136 ) 0.28 – 0.70 0.49 Balance, June 30, 2019 8,849,451 $0.23 – 1.65 $ 0.46 $ — Weighted Non-plan average Aggregate Options Exercise price per intrinsic As of June 30, 2018: outstanding price per share share value (1) Balance, December 31, 2017 20,018,408 $0.25 – 1.00 $ 0.51 Granted 1,008,268 0.23 – 0.43 0.26 Expired (2,400,000 ) 0.99 0.99 Balance, June 30, 2018 18,626,676 $0.25 – 1.00 $ 0.45 $ — As of June 30, 2019: Balance, December 31, 2018 19,319,496 $0.23 – 1.00 $ 0.43 Granted 970,380 0.16 – 0.25 0.19 Expired (691,975 ) 0.55 0.55 Balance, June 30, 2019 19,597,901 $0.16 – 1.00 $ 0.42 $ 34,000

Note 6 - Warrants (Tables)

Note 6 - Warrants (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Weighted average Aggregate Warrants Exercise price per intrinsic As of June 30, 2018: outstanding price per share share value (1) Balance, December 31, 2017 22,104,817 $0.125 – 1.00 $ 0.45 Issued 2,611,513 0.25 – 0.48 0.35 Expired (2,683,400 ) 0.40 0.40 Balance, June 30, 2018 22,032,930 $0.125 – 1.00 $ 0.44 As of June 30, 2019: Balance, December 31, 2018 26,872,430 $0.25 – 1.00 $ 0.42 Issued 9,031,871 0.10 – 0.25 0.15 Exercised (5,205,746 ) 0.10 – 0.12 0.11 Balance, June 30, 2019 30,698,555 $0.10 – 1.00 $ 0.39 $ 547,000
Schedule Of Assumptions Used To Determine Fair Value Of Warrants [Table Text Block]	June 30, 2018 June 30, 2019 Risk free interest rate 2.54% 1.70 – 2.62% Expected volatility 252% 86 – 110% Expected dividend yield — — Forfeiture rate — — Expected life in years 5 – 10 2 – 5

Note 7 - Accounts Payable and_2

Note 7 - Accounts Payable and Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	December 31, 2018 June 30, 2019 Accounts payable and accrued expense $ 302 $ 328 Accrued interest 122 209 Accrued payroll 77 139 Total accounts payable and accrued expenses $ 501 $ 676

Note 8 - Noncontrolling Inter_2

Note 8 - Noncontrolling Interest - Clyra Medical (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Other Ownership Interests [Table Text Block]	Shareholder Shares Percent BioLargo, Inc. 28,053 41.4% Sanatio Capital (1) 11,520 17.0% Scion Solutions (2) 15,500 22.9% Other 12,697 18.7% Total 67,770

Note 10 - Business Segment In_2

Note 10 - Business Segment Information (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three months ended June 30, Six months ended June 30, 2018 2019 2018 2019 Revenue Odor-No-More $ 316 $ 315 $ 540 $ 616 BLEST 161 241 350 424 BLEST - Intercompany revenue (150 ) (130 ) (300 ) (250 ) Total $ 327 $ 426 $ 590 $ 790 Operating loss BioLargo corporate $ (1,052 ) $ (956 ) $ (2,145 ) $ (1,904 ) Odor-No-More (145 ) (51 ) (254 ) (141 ) Clyra (177 ) (319 ) (376 ) (606 ) BLEST (70 ) (27 ) (115 ) (137 ) Water (184 ) (134 ) (340 ) (361 ) Total $ (1,628 ) $ (1,487 ) $ (3,230 ) $ (3,149 ) Interest expense BioLargo Corporate $ (1,729 ) $ (485 ) $ (2,559 ) $ (1,458 ) Clyra — (13 ) (2 ) (25 ) Total $ (1,729 ) $ (498 ) $ (2,561 ) $ (1,483 ) Research and development expense BioLargo Corporate $ (281 ) $ (210 ) $ (624 ) $ (382 ) Odor-No-More — — — — Clyra (57 ) (106 ) (144 ) (155 ) BLEST (105 ) (73 ) (205 ) (195 ) Water (132 ) (108 ) (274 ) (317 ) Intersegement BioLargo corporate 150 130 300 256 Total $ (425 ) $ (367 ) $ (947 ) $ (793 ) As of June 30, 2019 BioLargo ONM Clyra BLEST Water Elimination Total Tangible assets $ 1,000 $ 198 $ 302 $ 163 $ 33 $ (6 ) $ 1,690 Intangible assets 1,893 — — — — — 1,893 As of December 31, 2018 BioLargo ONM Clyra BLEST Water Elimination Total Tangible assets $ 353 $ 220 $ 462 $ 230 $ 33 $ (6 ) $ 1,292 Intangible assets 1,893 — — — — — 1,893

Note 1 - Business and Organiz_2

Note 1 - Business and Organization (Details Textual)	1 Months Ended	3 Months Ended				6 Months Ended		12 Months Ended
	Aug. 13, 2019USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Jun. 30, 2018USD ($)	Mar. 31, 2018USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Dec. 31, 2018USD ($)	Jul. 20, 2019
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total		$ (1,987,000)	$ (2,749,000)	$ (3,600,000)	$ (2,430,000)	$ (4,736,000)	$ (6,029,000)
Net Cash Provided by (Used in) Operating Activities, Total						(1,851,000)	(2,053,000)
Working Capital		3,473,000				3,473,000
Assets, Current, Total		1,001,000				1,001,000		$ 955,000
Revenue from Contract with Customer, Including Assessed Tax		426,000		$ 327,000		790,000	590,000	$ 1,364,000
Net Cash Provided by (Used in) Financing Activities, Total						1,924,000	$ 1,739,000
Cash, Ending Balance		$ 706,000				$ 706,000
Number of Wholly-Owned Subsidiaries		5				5
Clyra Medical Technology Inc [Member] | Biolargo [Member]
Noncontrolling Interest, Ownership Percentage by Parent		41.40%				41.40%
Subsequent Event [Member]
Net Cash Provided by (Used in) Financing Activities, Total	$ 2,540,000
Subsequent Event [Member] | Biolargo [Member]
Noncontrolling Interest, Ownership Percentage by Parent									38.90%
Convertible Notes Payable [Member]
Short-term Debt, Total		$ 1,724,000				$ 1,724,000
Debt Obligation Due Next 12 Months [Member]
Long-term Debt, Gross		2,119,000				2,119,000
Notes Payable, Maturing September 6, 2019 [Member]
Convertible Debt, Total		145,000				145,000
Line of Credit, Maturing 30 Day Demand Begining September 1, 2019 [Member]
Long-term Line of Credit, Total		$ 250,000				$ 250,000

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)	6 Months Ended		12 Months Ended
	Jun. 30, 2019USD ($)	Jun. 30, 2018	Dec. 31, 2018USD ($)	Mar. 31, 2019USD ($)
Cash, FDIC Insured Amount	$ 250,000
Inventory Valuation Reserves, Ending Balance	3,000		$ 3,000
Security Deposit	35,000
Impairment of Long-Lived Assets Held-for-use	$ 0		0
Number of Grants Received	60
Operating Lease, Right-of-Use Asset	$ 370,000
Accounts Receivable, Allowance for Credit Loss, Ending Balance	0		$ 0
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset				$ 399,000
Operating Lease, Liability, Total				$ 399,000
Canadian Government Grants [Member]
Grants Receivable	$ 3,600,000
Canadian Government Grants [Member] | Minimum [Member]
Grant Term	180 days
Canadian Government Grants [Member] | Maximum [Member]
Grant Term	1 year 180 days
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Number of Major Customers	2	2
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Number of Major Customers	2		4
Clyra Medical Technology Inc [Member] | Biolargo [Member]
Noncontrolling Interest, Ownership Percentage by Parent	41.40%

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Summary of Cash Balances (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017
Cash and Cash Equivalents	$ 706	$ 655	$ 651	$ 990
Parent Company [Member]
Cash and Cash Equivalents	553	193
Noncontrolling Interest [Member]
Cash and Cash Equivalents	$ 153	$ 462

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Credit Concentration (Details) - Customer Concentration Risk [Member]	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Customer A [Member] | Revenue from Contract with Customer Benchmark [Member]
Credit concentration	18.00%	43.00%
Customer W [Member] | Accounts Receivable [Member]
Credit concentration	11.00%	12.00%
Customer B [Member] | Revenue from Contract with Customer Benchmark [Member]
Credit concentration		15.00%
Customer B [Member] | Revenue from Contract with Customer Benchmark [Member] | Maximum [Member]
Credit concentration	10.00%
Customer X [Member] | Accounts Receivable [Member]
Credit concentration	10.00%	31.00%
Customer Y [Member] | Accounts Receivable [Member]
Credit concentration	10.00%	10.00%
Customer Z [Member] | Accounts Receivable [Member]
Credit concentration	10.00%	10.00%

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Raw material	$ 26	$ 14
Finished goods	12	12
Total	$ 38	$ 26

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Stock Options, Valuation Assumptions (Details)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Non Plan [Member]
Expected dividend yield
Life in years (Year)	7 years	7 years
Non Plan [Member] | Minimum [Member]
Risk free interest rate	2.00%	2.43%
Expected volatility	147.00%	548.00%
Non Plan [Member] | Maximum [Member]
Risk free interest rate	2.65%	2.91%
Expected volatility	152.00%	563.00%
2018 Equity Incentive Plan [Member]
Risk free interest rate		2.91%
Expected volatility		548.00%
Expected dividend yield
Life in years (Year)	7 years	7 years
2018 Equity Incentive Plan [Member] | Minimum [Member]
Risk free interest rate	2.00%
Expected volatility	147.00%
2018 Equity Incentive Plan [Member] | Maximum [Member]
Risk free interest rate	2.65%
Expected volatility	152.00%

Note 3 - Lincoln Park Financi_2

Note 3 - Lincoln Park Financing (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Aug. 25, 2017
Proceeds from Issuance of Common Stock		$ 381,000
Lincoln Park Capital Fund, LLC [Member]
Stock Purchase Agreement, Maximum Amount of Common Stock			$ 10,000,000
Stock Issued During Period, Shares, New Issues		1,256,751
Proceeds from Issuance of Common Stock		$ 381,000
Stock Issued During Period, Shares, Additional Commitment		18,260

Note 4 - Debt Obligations (Deta

Note 4 - Debt Obligations (Details Textual) - USD ($)

Jul. 29, 2019

Jul. 07, 2019

Jun. 17, 2019

Jun. 04, 2019

Apr. 18, 2019

Mar. 28, 2019

Mar. 14, 2019

Mar. 07, 2019

Feb. 05, 2019

Jan. 31, 2019

Jan. 07, 2019

Aug. 13, 2019

Jun. 30, 2019

Mar. 31, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Jan. 06, 2019

Dec. 31, 2018

Dec. 31, 2017

Gain (Loss) on Extinguishment of Debt, Total

$ (44,000)

$ (228,000)

Common Stock, Shares Authorized

400,000,000

400,000,000

400,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.39

$ 0.44

$ 0.39

$ 0.44

$ 0.42

$ 0.45

Maximum [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights

1

$ 1

1

$ 1

$ 1

$ 1

Warrant for OID Investor [Member]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.25

$ 0.25

Conversion of Principal Amount into Common Stock [Member]

Debt Conversion, Converted Instrument, Shares Issued

4,406,312

Conversion of OID Notes to Common Stock [Member]

Debt Instrument, Convertible, Conversion Price

$ 0.25

Debt Instrument, Term

270 days

Equity Offering Price, Conversion Price Adjustment Threshold

$ 0.25

Stock Purchase Warrant, Percentage of Principal

75.00%

Convertible Notes Payable [Member]

Short-term Debt, Total

$ 1,724,000

$ 1,724,000

Convertible Notes Payable [Member] | Convertible Note, Prepayment Period, First 90 Days [Member]

Debt Instrument, Convertible, Beneficial Conversion Feature

$ 120,000

Convertible Notes Payable [Member] | Convertible Note, Prepayment Period, First 90 Days [Member] | Maximum [Member]

Debt Instrument, Default, Interest Rate

24.00%

Convertible Notes Payable [Member] | Tangiers Global [Member]

Debt Instrument, Convertible, Conversion Price, Percentage of Lowest Closing Bid Price

75.00%

Debt Instrument, Convertible, Number of Consecutive Trade Days Prior to Conversion Date

25 days

Debt Instrument, Convertible, Default Penalty

22.00%

Debt Instrument, Convertible, Beneficial Conversion Feature

$ 185,000

Short-term Debt, Total

554,000

554,000

Proceeds from Convertible Debt

$ 150,000

$ 300,000

Debt Instrument, Face Amount

$ 330,000

Debt Instrument, Convertible, Interest Rate on Remaining Principal

12.00%

Debt Instrument, Convertible, Aggregate Principal Amount

$ 495,000

Original Issue Discount, Percentage

10.00%

Debt Instrument, Convertible, Days to Prepay Following Effective Date

180 days

Debt Instrument, Default, Percentage of Principal

25.00%

Common Stock, Shares Authorized

3,000,000

Convertible Notes Payable [Member] | Tangiers Global [Member] | Tangiers Global Convertible Note, Prepayment Period First 90 Days [Member]

Debt Instrument, Convertible, Prepayment Penalty

25.00%

Convertible Notes Payable [Member] | Tangiers Global [Member] | Tangiers Global Convertible Note Prepayment Period Second 90 Days [Member]

Debt Instrument, Convertible, Prepayment Penalty

30.00%

Convertible Notes Payable [Member] | Bellridge Capital, LP [Member]

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Debt Instrument, Convertible, Conversion Price, Percentage of Lowest Closing Bid Price

70.00%

Debt Instrument, Convertible, Number of Consecutive Trade Days Prior to Conversion Date

25 days

Proceeds from Convertible Debt

$ 188,000

Debt Instrument, Face Amount

$ 220,000

Original Issue Discount, Percentage

10.00%

Debt Instrument, Term

1 year

Debt Instrument, Fee Amount

$ 10,000

Additional Proceeds From Convertible Debt

$ 400,000

Convertible Notes Payable [Member] | Bellridge Capital, LP [Member] | Convertible Note, Prepayment Period, First 90 Days [Member]

Debt Instrument, Convertible, Prepayment Penalty

125.00%

Convertible Notes Payable [Member] | Bellridge Capital, LP [Member] | Convertible Note Prepayment Period, Second 90 Days [Member]

Debt Instrument, Convertible, Prepayment Penalty

130.00%

Promissory Notes Payable, Issued to Vernal Bay Investments, Originally Issued September 19, 2018 [Member]

Debt Instrument Extension Option Increase In Principal Percentage

10.00%

Promissory Notes Payable, Originally Issued September 19, 2018 [Member]

Debt Instrument, Face Value, After Increase from Maturity Date Extension

$ 484,000

Vista Capital 2017 Note [Member]

Debt Instrument Extension Option Increase In Principal Percentage

10.00%

Gain (Loss) on Extinguishment of Debt, Total

(38,000)

Debt Conversion, Original Debt, Amount

515,000

Vista Capital 2017 Note [Member] | Convertible Notes Payable [Member]

Short-term Debt, Total

$ 125,000

125,000

Vista Capital 2017 Note [Member] | Convertible Notes Payable [Member] | Vista Capital [Member]

Debt Instrument, Face Value, After Increase from Maturity Date Extension

$ 420,000

$ 605,100

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Debt Instrument, Convertible, Conversion Price, Percentage of Lowest Closing Bid Price

80.00%

Debt Instrument, Convertible, Number of Consecutive Trade Days Prior to Conversion Date

25 days

Debt Instrument, Convertible, Prepayment Penalty

15.00%

20.00%

Debt Instrument, Convertible, Default Penalty

25.00%

30.00%

Debt Instrument, Convertible, Beneficial Conversion Feature

$ 487,000

Vista Capital 2019 Note [Member] | Convertible Notes Payable [Member] | Vista Capital [Member]

Debt Instrument, Interest Rate, Stated Percentage

12.00%

Debt Instrument, Convertible, Conversion Price, Percentage of Lowest Closing Bid Price

65.00%

Debt Instrument, Convertible, Number of Consecutive Trade Days Prior to Conversion Date

25 days

Debt Instrument, Convertible, Beneficial Conversion Feature

$ 300,000

Proceeds from Convertible Debt

300,000

Debt Instrument, Face Amount

$ 330,000

Common Stock, Limit on Ownership Interest, Percent

4.99%

Convertible Twelve Months OID Notes [Member]

Debt Instrument, Interest Rate, Stated Percentage

5.00%

5.00%

Debt Instrument, Convertible, Beneficial Conversion Feature

$ 425,000

Proceeds from Convertible Debt

425,000

Debt Instrument, Face Amount

$ 531,000

$ 531,000

Original Issue Discount, Percentage

10.00%

Debt Instrument, Convertible, Conversion Price

$ 0.17

$ 0.17

Debt Instrument, Term

1 year

Debt Instrument, Unamortized Discount, Total

$ 106,000

$ 106,000

Amount of Qualifying Offering Needed to Trigger Note Prepayment

$ 3,500,000

$ 3,500,000

Debt Instrument, Convertible, Conversion Price, Percentage of Lowest Closing Volume Weighted Average Price

70.00%

70.00%

Debt Instrument, Convertible, Number of Consecutive Trade Days Preceding The Conversion

25 days

Convertible Twelve Months OID Notes [Member] | Four Accredited Investors [Member]

Original Issue Discount, Percentage

25.00%

25.00%

Convertible Promissory OID Note [Member]

Debt Instrument, Face Amount

$ 213,000

OID Note [Member] | Convertible Notes Payable [Member]

Original Issue Discount, Percentage

25.00%

Bellridge Note [Member]

Debt Instrument, Discount, Amortization Period

1 year

Convertible Note to Crossover Capital Fund I, LP [Member] | Convertible Notes Payable [Member]

Debt Instrument, Face Amount

$ 110,000

Original Issue Discount, Percentage

10.00%

Debt Instrument, Term

270 days

Proceeds from Short-term Debt, Total

$ 95,000

Payments of Debt Issuance Costs

$ 5,000

Convertible Note Related to Second Investment From Crossover Capital [Member]

Debt Instrument, Convertible, Conversion Price, Percentage of Lowest Closing Bid Price

70.00%

Debt Instrument, Convertible, Number of Consecutive Trade Days Prior to Conversion Date

25 days

Debt Instrument, Convertible, Beneficial Conversion Feature

$ 134,000

Proceeds from Convertible Debt

77,000

Debt Instrument, Face Amount

$ 90,000

Original Issue Discount, Percentage

10.00%

Debt Instrument, Term

270 days

Debt Instrument, Discount, Amortization Period

270 days

Payments of Debt Issuance Costs

$ 5,000

Convertible Note Related to Second Investment From Crossover Capital [Member] | Maximum [Member]

Debt Instrument, Convertible, Days to Prepay Following Effective Date

180 days

Debt Instrument, Default, Interest Rate

24.00%

Convertible Note, Prepayment Related to Crossover Capital Purchase Agreement, Within First Thirty Days [Member]

Debt Instrument, Convertible, Prepayment Penalty

5.00%

Convertible Note To EMA Financial, LLC [Member]

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Debt Instrument, Convertible, Conversion Price, Percentage of Lowest Closing Bid Price

70.00%

Debt Instrument, Convertible, Number of Consecutive Trade Days Prior to Conversion Date

25 days

Debt Instrument, Convertible, Prepayment Penalty

30.00%

Debt Instrument, Convertible, Beneficial Conversion Feature

$ 77,000

Proceeds from Convertible Debt

95,000

Debt Instrument, Face Amount

$ 110,000

Debt Instrument, Term

270 days

Payments of Debt Issuance Costs

$ 5,000

Convertible Note To EMA Financial, LLC [Member] | Maximum [Member]

Debt Instrument, Convertible, Prepayment Penalty

24.00%

Debt Instrument, Convertible, Days to Prepay Following Effective Date

90 days

Convertible Note To EMA Financial, LLC, First 90 days [Member]

Debt Instrument, Convertible, Prepayment Penalty

125.00%

Convertible Note To EMA Financial, LLC, Second 90 days [Member]

Debt Instrument, Convertible, Prepayment Penalty

130.00%

Promissory Notes Payable, Issued to Chappy Bean, Originally Issued September 19, 2018 [Member]

Debt Instrument Extension Option Increase In Principal Percentage

10.00%

Subsequent Event [Member]

Proceeds from Debt, Net of Issuance Costs

$ 2,360,000

Subsequent Event [Member] | Warrants In Connection With OID Notes [Member]

Class of Warrant or Right, Increase Shares Available for Purchase

300,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.25

Subsequent Event [Member] | Conversion of OID Notes to Common Stock [Member]

Debt Instrument, Convertible, Conversion Price

$ 0.17

Subsequent Event [Member] | Tangiers Global [Member] | Conversion Debt to Equity [Member]

Debt Conversion, Original Debt, Amount

$ 369,600

Subsequent Event [Member] | Convertible Twelve Months OID Notes [Member]

Debt Instrument, Face Amount

$ 1,762,500

Subsequent Event [Member] | Convertible Twelve Months OID Notes [Member] | Tangiers Global [Member]

Proceeds from Convertible Debt

350,000

Debt Instrument, Face Amount

$ 437,500

Subsequent Event [Member] | OID Note [Member]

Debt Instrument, Term

1 year

Note 4 - Debt Obligations - Sch

Note 4 - Debt Obligations - Schedule of Debt (Details) - USD ($) $ in Thousands		Jun. 30, 2019	Dec. 31, 2018
Notes payable		$ 534	$ 400
Total notes payable and line of credit		1,971	830
Convertible notes		2,863	1,365
Total current liabilities		4,834	2,195
Long-term Debt, Excluding Current Maturities, Total		210	1,292
Convertible notes		5,044	3,487
Notes Payable, Maturing June 6, 2019 [Member]
Notes payable		484	400
Note Payable, Maturing March 8, 2023 [Member]
Notes payable		50
Line of Credit, Maturing September 1, 2019 [Member]
Long-term Line of Credit, Total		430	430
Convertible Notes Issued by Clyra Medical Maturing on June 17, 2020 [Member]
Notes payable		1,007
Long-term Debt, Excluding Current Maturities, Total			1,007
Convertible Notes Maturing January 11, 2019 [Member]
Convertible notes			300
Convertible Notes Maturing on December 31, 2019 [Member]
Convertible notes		75	75
Convertible Note, Maturing on July 15, 2019 [Member]
Convertible notes		125	550
Convertible Notes, Maturing July 20, 2019 [Member]
Convertible notes	[1]	440	440
Convertible Note, Maturing October 7, 2019 [Member]
Convertible notes		370
Convertible Note, Maturing on July 15, 2019 and December 7, 2019 [Member]
Convertible notes		554
Convertible Nine Month OID Note, Maturing October, 2019 [Member]
Convertible notes		213
Convertible Note Maturing April 18, 2020 [Member]
Convertible notes		220
Convertible Note Maturing February 14 and March 17, 2020 [Member]
Convertible notes		200
Convertible Note Maturing March 4, 2020 [Member]
Convertible notes		110
Convertible Twelve Months OID Notes [Member]
Convertible notes		531
Convertible Notes, Maturing on June 20, 2020 [Member]
Convertible notes	[1]	25
Long-term Debt, Excluding Current Maturities, Total			25
Convertible Notes, Maturing April 20, 2021 [Member]
Long-term Debt, Excluding Current Maturities, Total		100	100
Convertible Notes, Mature June 15, 2021 [Member]
Long-term Debt, Excluding Current Maturities, Total		110	110
Convertible Note, Maturing On March 8, 2023 [Member]
Long-term Debt, Excluding Current Maturities, Total			$ 50
[1]	These notes are convertible at our option at maturity.

Note 5 - Share-based Compensa_3

Note 5 - Share-based Compensation (Details Textual) - USD ($)	Jul. 05, 2019	Jun. 28, 2019	May 28, 2019	Mar. 31, 2019	Mar. 29, 2019	Jan. 16, 2019	Jun. 30, 2018	Jun. 29, 2018	Jun. 22, 2018	Sep. 07, 2017	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Stock Issued During Period, Value, Issued for Services											$ 213,000	$ 206,000	$ 250,000	$ 196,000
Stock Issued During Period, Value, New Issues													$ 212,000	$ 168,000
Share Price						$ 0.22
2018 Equity Incentive Plan [Member]
Shares Issued, Price Per Share									$ 0.23
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period									10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized									40,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Per Year									2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						300,000	296,976								3,728,366
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price															$ 0.18
The 2007 Equity Incentive Plan [Member]
Shares Issued, Price Per Share											$ 0.23				0.23
Non Plan [Member]
Shares Issued, Price Per Share											$ 0.23				$ 0.23
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross															970,380	1,008,268
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price															$ 0.19	$ 0.26
Selling, General and Administrative Expenses [Member]
Share-based Payment Arrangement, Expense															$ 648,000	$ 696,000
Sale of Products and License of Technology [Member]
Contract with Customer, Liability, Revenue Recognized			$ 3,000,000
Restricted Stock Units (RSUs) [Member] | Vice President of Operation and President of Subsidiary [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			500,000
Proceeds Cash, Trigger for Award as Unvested			$ 3,000,000
Common Stock Issued for Accrued Interest Due on Promissory Note [Member]
Stock Issued During Period, Shares, New Issues											87,478		1,302,734
Stock Issued During Period, Value, New Issues											$ 15,000		$ 329,000
Minimum [Member] | Common Stock Issued for Accrued Interest Due on Promissory Note [Member]
Shares Issued, Price Per Share							$ 0.23				$ 0.23		$ 0.23		$ 0.23	$ 0.23
Maximum [Member] | The 2007 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period										10 years
Maximum [Member] | Common Stock Issued for Accrued Interest Due on Promissory Note [Member]
Shares Issued, Price Per Share							0.45				$ 0.43		$ 0.45		0.43	0.45
Officer [Member]
Stock Issued During Period, Shares, Issued for Services		465,875		323,030	579,996			176,947
Stock Issued During Period, Value, Issued for Services		$ 107,000		$ 84,000	$ 93,000			$ 76,000
Shares Issued, Price Per Share		$ 0.23		$ 0.26	$ 0.16			$ 0.43				$ 0.26
Consultants [Member]
Stock Issued During Period, Shares, Issued for Services											515,809		556,874
Stock Issued During Period, Value, Issued for Services											$ 107,000		$ 174,000
Consultants [Member] | Minimum [Member]
Shares Issued, Price Per Share							0.17				$ 0.16		$ 0.17		0.16	0.17
Consultants [Member] | Maximum [Member]
Shares Issued, Price Per Share							0.23				0.23		0.23		$ 0.23	$ 0.23
Employees, Consultations, Offers, and Directors [Member] | 2018 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross															3,528,366
Employees and Consultants [Member] | 2018 Equity Incentive Plan [Member]
Share-based Payment Arrangement, Expense															$ 93,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross															513,012
Employees and Consultants [Member] | Minimum [Member] | 2018 Equity Incentive Plan [Member]
Shares Issued, Price Per Share											0.16				$ 0.16
Employees and Consultants [Member] | Maximum [Member] | 2018 Equity Incentive Plan [Member]
Shares Issued, Price Per Share											0.25				$ 0.25
Board Of Directors [Member] | 2018 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross															715,354
Board Of Directors [Member] | Minimum [Member] | 2018 Equity Incentive Plan [Member]
Shares Issued, Price Per Share											0.16				$ 0.16
Board Of Directors [Member] | Maximum [Member] | 2018 Equity Incentive Plan [Member]
Shares Issued, Price Per Share											0.23				$ 0.23
Chief Financial Officer [Member] | 2018 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross															300,000
Share Price											0.22				$ 0.22
Chief Financial Officer [Member] | Equity Incentive Plan 2007 [Member]
Share-based Payment Arrangement, Expense															$ 67,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares															75,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Remaining Number of Shares to Vest Each Month						25,000
Chief Financial Officer [Member] | Selling, General and Administrative Expenses [Member] | Equity Incentive Plan 2007 [Member]
Share-based Payment Arrangement, Expense															$ 50,000
Vice President of Operations [Member] | 2018 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross															1,000,000
Share Price											0.17				$ 0.17
Vice President of Sales [Member] | 2018 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			1,200,000												1,200,000
Share Price			$ 0.17								0.17				$ 0.17
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares			200,000
Vice President of Sales [Member] | 2018 Equity Incentive Plan [Member] | Vesting At Various Metrics [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares			1,000,000
Vice President of Sales [Member] | 2018 Equity Incentive Plan [Member] | Vesting At Various Metrics [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	300,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	100,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.25
Vice President of Sales [Member] | Selling, General and Administrative Expenses [Member] | 2018 Equity Incentive Plan [Member]
Share-based Payment Arrangement, Expense															$ 137,000
Vice President of Sales [Member] | Selling, General and Administrative Expenses [Member] | 2018 Equity Incentive Plan [Member] | Vesting Immediately [Member]
Share-based Payment Arrangement, Expense			$ 34,000
Vice President of Operation and President of Subsidiary [Member] | 2018 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			1,200,000
Vice President of Operation and President of Subsidiary [Member] | 2018 Equity Incentive Plan [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	300,000
Share-based Payment Arrangement, Amortization Term	91 days
Share-based Compensation Arrangement by Share-based Payment Award Options Annual Vesting Installment Shares	100,000
Vice President of Operation and President of Subsidiary [Member] | 2018 Equity Incentive Plan [Member] | Vesting Annually [Member]
Share Price			$ 0.17
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares			200,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			3 years
Vice President of Operation and President of Subsidiary [Member] | 2018 Equity Incentive Plan [Member] | Vesting At Various Metrics [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			1,000,000
Vice President of Operation and President of Subsidiary [Member] | Maximum [Member] | 2018 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			1 year
Vendors [Member] | Non Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross															970,380
Vendors [Member] | Share-based Payment Arrangement, Option [Member] | Non Plan [Member]
Share-based Payment Arrangement, Expense															$ 194,000
Vendors [Member] | Share-based Payment Arrangement, Option [Member] | Selling, General and Administrative Expenses [Member] | Non Plan [Member]
Share-based Payment Arrangement, Expense															$ 367,000
Vendors [Member] | Minimum [Member] | Non Plan [Member]
Shares Issued, Price Per Share											0.16				$ 0.16
Vendors [Member] | Maximum [Member] | Non Plan [Member]
Shares Issued, Price Per Share											$ 0.25				$ 0.25
Board of Directors and Vendors [Member] | Non Plan [Member]
Stock Issued During Period, Value, Issued for Services																$ 261,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																1,008,268
Board of Directors and Vendors [Member] | Minimum [Member] | Non Plan [Member]
Shares Issued, Price Per Share							0.23						0.23			$ 0.23
Board of Directors and Vendors [Member] | Maximum [Member] | Non Plan [Member]
Shares Issued, Price Per Share							$ 0.43						$ 0.43			$ 0.43

Note 5 - Share-based Compensa_4

Note 5 - Share-based Compensation - Stock Options (Details) - USD ($)		Jan. 16, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Options outstanding, balance (in shares)
Exercise price per share, balance (in dollars per share)
2018 Equity Incentive Plan [Member]
Options outstanding, balance (in shares)				1,318,517
Options outstanding, balance (in shares)		300,000	296,976	3,728,366
Aggregate intrinsic value, balance	[1]					$ 109,000
Weighted average price per share, balance (in dollars per share)				$ 0.30		$ 0.21
Weighted average price per share, granted (in dollars per share)				0.18
Weighted average price per share, balance (in dollars per share)				$ 0.30
Options outstanding, balance (in shares)			296,976	5,046,833	296,976
Exercise price per share, balance (in dollars per share)			$ 0.43		$ 0.43
Weighted average price per share, balance (in dollars per share)				$ 0.21
2018 Equity Incentive Plan [Member] | Minimum [Member]
Exercise price per share, balance (in dollars per share)				0.22
Exercise price per share, balance (in dollars per share)			0.43	0.16
Exercise price per share, balance (in dollars per share)				0.16
2018 Equity Incentive Plan [Member] | Maximum [Member]
Exercise price per share, balance (in dollars per share)				0.43
Exercise price per share, balance (in dollars per share)			$ 0.43	0.22
Exercise price per share, balance (in dollars per share)				$ 0.43
Equity Incentive Plan 2007 [Member]
Options outstanding, balance (in shares)				9,691,586	9,831,586
Exercise price per share, balance (in dollars per share)				$ 0.43	$ 1.89
Aggregate intrinsic value, balance	[1]
Weighted average price per share, balance (in dollars per share)
Weighted average price per share, balance (in dollars per share)
Options outstanding, expired (in shares)				(842,136)	(70,000)
Exercise price per share, expired (in dollars per share)				$ 0.49	$ 1.79
Weighted average price per share, expired (in dollars per share)
Options outstanding, balance (in shares)			9,761,586	8,849,451	9,761,586
Exercise price per share, balance (in dollars per share)			$ 0.43	$ 0.46	$ 0.43
Equity Incentive Plan 2007 [Member] | Minimum [Member]
Exercise price per share, balance (in dollars per share)				0.23	0.23
Exercise price per share, expired (in dollars per share)				0.28	1.45
Exercise price per share, balance (in dollars per share)			0.23	0.23	0.23
Equity Incentive Plan 2007 [Member] | Maximum [Member]
Exercise price per share, balance (in dollars per share)				0.94	0.44
Exercise price per share, expired (in dollars per share)				0.70	1.89
Exercise price per share, balance (in dollars per share)			1.65	$ 1.65	$ 1.65
Non Plan [Member]
Options outstanding, balance (in shares)				19,319,496	20,018,408
Options outstanding, balance (in shares)				970,380	1,008,268
Aggregate intrinsic value, balance	[1]					$ 34,000
Weighted average price per share, balance (in dollars per share)			$ 0.45	$ 0.43	$ 0.51	$ 0.42	$ 0.45
Weighted average price per share, granted (in dollars per share)				0.19	0.26
Weighted average price per share, balance (in dollars per share)				$ 0.43	$ 0.51
Options outstanding, expired (in shares)				(691,975)	(2,400,000)
Exercise price per share, expired (in dollars per share)				$ 0.55	$ 0.99
Weighted average price per share, expired (in dollars per share)				$ 0.55	$ 0.99
Options outstanding, balance (in shares)			18,626,676	19,597,901	18,626,676
Weighted average price per share, balance (in dollars per share)			$ 0.45	$ 0.42	$ 0.45
Non Plan [Member] | Minimum [Member]
Exercise price per share, balance (in dollars per share)				0.23	0.25
Exercise price per share, balance (in dollars per share)				0.16	0.23
Exercise price per share, balance (in dollars per share)			0.25	0.16	0.25
Non Plan [Member] | Maximum [Member]
Exercise price per share, balance (in dollars per share)				1	1
Exercise price per share, balance (in dollars per share)				0.25	0.43
Exercise price per share, balance (in dollars per share)			$ 1	$ 1	$ 1
[1]	Aggregate intrinsic value based on closing common stock price of $0.23 at June 30, 2019.

Note 6 - Warrants (Details Text

Note 6 - Warrants (Details Textual) - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Mar. 05, 2019	Mar. 04, 2019	Jan. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.39		$ 0.44	$ 0.39	$ 0.44				$ 0.42	$ 0.45
Gain (Loss) on Extinguishment of Debt, Total	$ (44,000)			$ (228,000)
Deemed Dividends	355,000			782,000	297,000
Proceeds from Warrant Exercises	$ 104,000			$ 104,000
Stock Issued During Period, Shares, Exercise of Warrants	866,666
Nine Months OID Notes In Connection With Warrant [Member]
Debt Instrument, Convertible, Conversion Price	$ 0.17	$ 0.25		$ 0.17
Warrants Issued as Part of Debt Extension [Member]
Gain (Loss) on Extinguishment of Debt, Total		$ (56,000)
Aggregated Number of Shares Purchased Under Two Warrants		496,875
Warrants Issued Concurrently with the Nine-month Note Payable [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		637,500
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.25
Warrants and Rights Outstanding, Term		5 years
Discount On Convertible Note Payable		$ 89,000
Nine Months OID Notes In Connection With Warrant [Member]
Class of Warrant or Right, Number of Securities Authorized	937,500	300,000
Deemed Dividends				$ 85,000
Twelve Months OID Notes In Connection With Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,619,485			2,619,485
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.25			$ 0.25
Warrants and Rights Outstanding, Term	5 years			5 years
Stock Purchase Warrant, Percentage of Principal	75.00%			75.00%
Class of Warrant or Right, Percentage of Principal Value of Note Calculation, Investment	$ 300,000			$ 300,000
Class of Warrant or Right, Percentage of Principal Value of Note Calculation, Numerator Value of Calculation	$ 375,000			$ 375,000
Class of Warrant or Right, Percentage of Principal Value of Note Calculation, Denominator Value of Calculation	1,654,412			1,654,412
Discount on Notes Payable	$ 252,000			$ 252,000
Vista Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,877,790			2,877,790
Vernal Bay Investments, LLC [Member] | Warrants Issued as Part of Debt Extension [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						1,734,375	1,387,500
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 0.20	$ 0.25
Maximum Investment Amount under Warrant						$ 346,875
Chappy Bean, LLC [Member] | Warrants Issued as Part of Debt Extension [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						750,000	600,000
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 0.20
Lincoln Park Capital Fund, LLC [Member] | Warrants Issued as Consent for Variable Rate Date [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								300,000
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.25
Warrants and Rights Outstanding, Term								5 years
Discount On Convertible Note Payable								$ 54,000

Note 6 - Warrants - Warrants Ou

Note 6 - Warrants - Warrants Outstanding (Details) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Balance, outstanding (in shares)	26,872,430	22,104,817
Balance, outstanding, price range (in dollars per share)	$ 0.42	$ 0.45
Issued (in shares)	9,031,871	2,611,513
Issued, price range (in dollars per share)	$ 0.15	$ 0.35
Expired (in shares)	(5,205,746)	(2,683,400)
Expired, price range (in dollars per share)	$ 0.11	$ 0.40
Balance, outstanding (in shares)	30,698,555	22,032,930
Balance, outstanding, price range (in dollars per share)	$ 0.39	$ 0.44
Balance	$ 547,000
Minimum [Member]
Balance, outstanding, price range (in dollars per share)	$ 0.25	0.125
Issued, price range (in dollars per share)	0.10	0.25
Expired, price range (in dollars per share)	0.10
Balance, outstanding, price range (in dollars per share)	0.10	0.125
Maximum [Member]
Balance, outstanding, price range (in dollars per share)	1	1
Issued, price range (in dollars per share)	0.25	0.48
Expired, price range (in dollars per share)	0.12
Balance, outstanding, price range (in dollars per share)	$ 1	$ 1

Note 6 - Warrants - Assumptions

Note 6 - Warrants - Assumptions Used to Determine Fair Value of Warrants (Details)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Risk free interest rate		2.54%
Expected volatility		252.00%
Minimum [Member]
Risk free interest rate	1.70%
Expected volatility	86.00%
Expected life (Year)	2 years	5 years
Maximum [Member]
Risk free interest rate	2.62%
Expected volatility	110.00%
Expected life (Year)	5 years	10 years

Note 7 - Accounts Payable and_3

Note 7 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Accounts payable and accrued expense	$ 328	$ 302
Accrued interest	209	122
Accrued payroll	139	77
Total accounts payable and accrued expenses	$ 676	$ 501

Note 8 - Noncontrolling Inter_3

Note 8 - Noncontrolling Interest - Clyra Medical (Details Textual) - USD ($)	Dec. 17, 2018	Sep. 26, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Long-term Debt, Excluding Current Maturities, Total			$ 210,000		$ 1,292,000
Proceeds from Issuance of Common Stock				$ 381,000
Preferred Stock, Shares Outstanding, Ending Balance			0		0
Convertible Notes Issued by Clyra Medical Maturing on June 17, 2020 [Member]
Long-term Debt, Excluding Current Maturities, Total					$ 1,007,000
Clyra Medical Technology Inc [Member] | Sanatio [Member]
Common Stock, Shares, Outstanding, Ending Balance			1,690
Preferred Stock, Dividend Rate, Percentage			8.00%
Preferred Shares Dividend, Period			5 years
Dividends Payable, Current			$ 215,000
Clyra Medical Technology Inc [Member] | Sanatio [Member] | Preferred Class A [Member]
Preferred Stock, Shares Outstanding, Ending Balance			9,830
Scion Acquisition [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		21,000
Business Combination, Consideration Transferred, Liabilities Incurred		$ 1,250,000
Business Acquisition, Base Capital Requirement for Escrow Release	$ 1,000,000	1,000,000
Business Acquisition, Gross Revenue, Tranche One	100,000
Business Acquisition, Gross Revenue, Tranche Two	100,000
Business Acquisition, Gross Revenue, Tranche Three	500,000
Business Acquisition, Gross Revenue, Tranche Five	$ 2,000,000
Scion Acquisition [Member] | Convertible Notes Issued by Clyra Medical Maturing on June 17, 2020 [Member]
Long-term Debt, Excluding Current Maturities, Total			$ 1,007,000
Proceeds from Issuance of Common Stock			$ 295,000
Shares Issued, Price Per Share			$ 200
Scion Acquisition [Member] | Clyra [Member]
Debt Instrument, Face Amount		$ 1,250,000
Debt Instrument, Interest Rate, Stated Percentage		5.00%
Debt Instrument, Percent of Investment Proceeds		25.00%
Debt Instrument, Extension Period		1 year
Debt Instrument, Term		1 year 180 days
Debt Instrument, Percent of Gross Revenue		5.00%
Scion Acquisition [Member] | Clyra Acquisition, Common Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	15,500	10,000	15,500
Scion Acquisition [Member] | Clyra Acquisition, Common Stock Redeemable for BioLargo Common Shares [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		7,142,858

Note 8 - Noncontrolling Inter_4

Note 8 - Noncontrolling Interest - Clyra Medical Common and Preferred Shares Outstanding (Details) - Clyra Medical Technology Inc [Member]	Jun. 30, 2019shares
Shares, Outstanding (in shares)	67,770
Biolargo [Member]
Shares, Outstanding (in shares)	28,053
Percent	41.40%
Sanatio [Member]
Shares, Outstanding (in shares)	11,520	[1]
Percent	17.00%	[1]
Scion Solutions [Member]
Shares, Outstanding (in shares)	15,500	[2]
Percent	22.90%	[2]
Other [Member]
Shares, Outstanding (in shares)	12,697
Percent	18.70%
[1]	Includes 9,830 Series A Preferred shares (see below), and 1,690 common shares.
[2]	Does not include an additional 15,500 shares held in escrow subject to performance metrics.

Note 9 - BioLargo Engineering_2

Note 9 - BioLargo Engineering, Science and Technologies, LLC (Details Textual) shares in Millions	1 Months Ended
	Sep. 30, 2017shares
Seven Employees Working at BioLargo Engineering, Science & Technologies, LLC [Member]
Deferred Compensation Arrangement with Individual, Requisite Service Period	5 years
Potential Ownership Percentage of Subsidiary Held by Subsidiary Employees Based on Performance	30.00%
Incentive Issuance Stipulations for Subsidiary Employees, Accounts Receivable Collected by Year One of Operation	90.00%
Incentive Issuance Stipulations for Subsidiary Employees, Profit Earned in Year One of Operation	10.00%
Seven Employees Working at BioLargo Engineering, Science & Technologies, LLC [Member] | Non-Qualified Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	5 years
BioLargo Engineering, Science & Technologies, LLC [Member]
Noncontrolling Interest, Ownership Percentage by Parent	100.00%
Leased Property in Knoxville, Tennessee for BioLargo Engineering, Science & Technologies, LLC [Member]
Lessee, Operating Lease, Term of Contract	3 years

Note 10 - Business Segment In_3

Note 10 - Business Segment Information (Details Textual)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Number of Operating Segments			4
Payments of Distributions to Affiliates			$ 54,000		$ 417,000
Revenue from Contract with Customer, Including Assessed Tax	$ 426,000	$ 327,000	$ 790,000	$ 590,000	1,364,000
Odor-No-More [Member]
Revenue from Contract with Customer, Including Assessed Tax					$ 1,000,000	$ 500,000

Note 10 - Business Segment In_4

Note 10 - Business Segment Information - Segment Information (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Revenue	$ 426,000	$ 327,000	$ 790,000	$ 590,000	$ 1,364,000
Operating loss	(1,487,000)	(1,628,000)	(3,149,000)	(3,230,000)
Interest expense	(498,000)	(1,729,000)	(1,483,000)	(2,561,000)
Research and development	(367,000)	(425,000)	(793,000)	(947,000)
Tangible assets	1,690,000		1,690,000		1,292,000
Intangible assets	1,893,000		1,893,000		1,893,000
Corporate, Non-Segment [Member]
Operating loss	(956,000)	(1,052,000)	(1,904,000)	(2,145,000)
Interest expense	(485,000)	(1,729,000)	(1,458,000)	(2,559,000)
Research and development	(210,000)	(281,000)	(382,000)	(624,000)
Tangible assets	1,000,000		1,000,000		353,000
Intangible assets	1,893,000		1,893,000		1,893,000
Consolidation, Eliminations [Member]
Tangible assets	(6,000)		(6,000)		(6,000)
Intangible assets
Intersegment Eliminations [Member]
Research and development	130,000	150,000	256,000	300,000
Odor-No-More [Member]
Revenue					1,000,000	$ 500,000
Odor-No-More [Member] | Operating Segments [Member]
Revenue	315,000	316,000	616,000	540,000
Operating loss	(51,000)	(145,000)	(141,000)	(254,000)
Research and development
Tangible assets	198,000		198,000		220,000
Intangible assets
Clyra [Member] | Operating Segments [Member]
Tangible assets	302,000		302,000		462,000
Intangible assets
BLEST [Member] | Operating Segments [Member]
Tangible assets	163,000		163,000		230,000
Intangible assets
BioLargo Water [Member] | Operating Segments [Member]
Operating loss	(134,000)	(184,000)	(361,000)	(340,000)
Research and development	(108,000)	(132,000)	(317,000)	(274,000)
Tangible assets	33,000		33,000		33,000
Intangible assets
BioLargo Engineering, Science & Technologies, LLC [Member] | Operating Segments [Member]
Revenue	241,000	161,000	424,000	350,000
Operating loss	(27,000)	(70,000)	(137,000)	(115,000)
Research and development	(73,000)	(105,000)	(195,000)	(205,000)
BioLargo Engineering, Science & Technologies, LLC [Member] | Intersegment Eliminations [Member]
Revenue	(130,000)	(150,000)	(250,000)	(300,000)
Clyra Segment [Member] | Operating Segments [Member]
Operating loss	(319,000)	(177,000)	(606,000)	(376,000)
Interest expense	(13,000)		(25,000)	(2,000)
Research and development	$ (106,000)	$ (57,000)	$ (155,000)	$ (144,000)

Note 11 - Commitments and Con_2

Note 11 - Commitments and Contingencies (Details Textual) - USD ($)	Jun. 18, 2019	Jun. 30, 2019	Jun. 30, 2018
Operating Leases, Rent Expense, Total		$ 104,000	$ 108,000
Lessee, Operating Lease, Renewal Term		4 years
Lessee, Operating Lease, Discount Rate		18.00%
Lessee, Operating Lease, Liability, Payments, Due, Total		$ 699,000
Consulting Services, Monthly Payment		$ 23,000
Consulting Services, Period of Services		4 years
Contractual Obligation, Total		$ 1,100,000
President and Chief Executive Officer [Member]
Employment Agreement, Annual Base Compensation	$ 169,772
Employment Agreement, Term	5 years

Note 12 - Subsequent Events (De

Note 12 - Subsequent Events (Details Textual) - USD ($)	Aug. 09, 2019	Jul. 29, 2019	Jul. 20, 2019	Aug. 13, 2019	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 04, 2019	Dec. 31, 2018	Dec. 31, 2017
Proceeds from Warrant Exercises					$ 104,000	$ 104,000
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.39	$ 0.39	$ 0.44		$ 0.42	$ 0.45
Convertible Twelve Months OID Notes [Member]
Proceeds from Convertible Debt					$ 425,000
Debt Instrument, Face Amount					$ 531,000	$ 531,000
Debt Instrument, Term					1 year
Debt Instrument, Convertible, Conversion Price					$ 0.17	$ 0.17
Original Issue Discount, Percentage								10.00%
Debt Instrument, Interest Rate, Stated Percentage					5.00%	5.00%
Subsequent Event [Member]
Proceeds From Investments				$ 2,360,000
Proceeds from Warrant Exercises				180,000
Cash, Period Increase (Decrease), Total				2,540,000
Aggregate Amount of Refinance Convert Current Liabilities				1,313,800
Subsequent Event [Member] | Promissory Note Due February 28, 2020 [Member]
Long-term Debt, Gross				125,000
Subsequent Event [Member] | Promissory Note Due April 7, 2020 [Member]
Long-term Debt, Gross				$ 330,000
Subsequent Event [Member] | Biolargo [Member]
Minority Interest Ownership Percentage Decrease By Parent			3.00%
Noncontrolling Interest, Ownership Percentage by Parent			38.90%
Subsequent Event [Member] | Conversion of Convertible Notes Payable into Common Stock [Member]
Debt Conversion, Original Debt, Amount		$ 330,000
Debt Conversion, Converted Instrument, Shares Issued		2,640,000
Subsequent Event [Member] | Conversion of Convertible Notes Payable into Common Stock [Member] | One Note Holder [Member]
Debt Conversion, Original Debt, Amount			$ 440,000
Debt Conversion, Converted Instrument, Shares Issued			2,000
Subsequent Event [Member] | Conversion of Convertible Notes Payable into Common Stock [Member] | Tangiers Global [Member]
Debt Conversion, Converted Instrument, Shares Issued		1,930,147
Subsequent Event [Member] | Conversion of Accrued Interest to Common Stock [Member]
Debt Conversion Accrued Interest Amount		$ 39,600
Subsequent Event [Member] | Conversion of Secured Line of Credit to Twelve Month OID Notes [Member] | Three Holders [Member]
Debt Conversion, Original Debt, Amount		$ 205,000
Subsequent Event [Member] | Conversion of Accrued and Unpaid Interest into Common Stock [Member] | One Note Holder [Member]
Debt Instrument, Convertible, Conversion Price			$ 0.2743
Debt Conversion Accrued Interest Amount			$ 105,600
Debt Conversion, Converted Instrument, Shares Issued			384,980
Subsequent Event [Member] | Conversion of Principal and Accrued Interest to Restated Note [Member]
Debt Instrument, Convertible, Conversion Price			$ 0.17
Debt Conversion, Principal and Accrued Interest Amount			$ 41,200
Subsequent Event [Member] | Warrants In Connection With OID Notes [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				7,775,735
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.25
Subsequent Event [Member] | Warrants In Connection With OID Notes [Member] | Three Holders [Member]
Class of Warrant or Right, Number of Securities Authorized		1,130,515
Subsequent Event [Member] | Warrant Related to Restated Note [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			2,095,588
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.25
Warrants and Rights Outstanding, Term			5 years
Subsequent Event [Member] | One accredited Investor [Member]
Stock Issued During Period, Shares, Warrants Exercised				1,500,000
Stock Issued During Period, Value, Warrants Exercised				$ 180,000
Subsequent Event [Member] | One accredited Investor [Member] | Conversion of Convertible Notes Payable into Common Stock [Member]
Debt Instrument, Convertible, Conversion Price	$ 0.30
Subsequent Event [Member] | One accredited Investor [Member] | Warrant In Connection With Convertible Note [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,200,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.30
Warrants and Rights Outstanding, Term	5 years
Subsequent Event [Member] | Convertible Twelve Months OID Notes [Member]
Debt Instrument, Face Amount				1,762,500
Subsequent Event [Member] | Convertible Twelve Months OID Notes [Member] | Three Holders [Member]
Debt Instrument, Face Amount		$ 256,250
Subsequent Event [Member] | Convertible Twelve Months OID Notes [Member] | Tangiers Global [Member]
Proceeds from Convertible Debt		350,000
Debt Instrument, Face Amount		$ 437,500
Subsequent Event [Member] | Convertible Twelve Months OID Notes [Member] | Three accredited Investors [Member]
Proceeds from Convertible Debt				1,410,000
Subsequent Event [Member] | Convertible Note [Member] | One accredited Investor [Member]
Proceeds from Convertible Debt	$ 600,000
Debt Instrument, Face Amount	$ 600,000
Debt Instrument, Term	2 years
Debt Instrument, Accrued Interest, Percentage, Monthly	15.00%
Subsequent Event [Member] | Notes payable, mature September 6, 2019 [Member]
Debt Instrument, Face Amount			$ 338,800
Original Issue Discount, Percentage			25.00%
Debt Instrument, Interest Rate, Stated Percentage			18.00%
Subsequent Event [Member] | Restated Note [Member]
Debt Instrument, Face Amount			$ 475,000
Debt Instrument, Interest Rate, Stated Percentage			5.00%
Subsequent Event [Member] | Current Liabilities [Member]
Conversion, Refinanced of Warrant, Aggregate Value				1,313,800
New Investments and Refinancing Activities				2,931,250
Subsequent Event [Member] | Noncurrent Liabilities [Member]
New Investments and Refinancing Activities				$ 600,000